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The C-terminal domain (CTD) of the largest subunit of RNA polymerase II (Pol II) is a
regulatory hub for transcription and RNA processing. Here, we identify PHD-finger protein 3
(PHF3) as a regulator of transcription and mRNA stability that docks onto Pol II CTD through
its SPOC domain. We characterize SPOC as a CTD reader domain that preferentially binds
two phosphorylated Serine-2 marks in adjacent CTD repeats. PHF3 drives liquid-liquid phase
separation of phosphorylated Pol II, colocalizes with Pol II clusters and tracks with Pol II
across the length of genes. PHF3 knock-out or SPOC deletion in human cells results in
increased Pol II stalling, reduced elongation rate and an increase in mRNA stability, with
marked derepression of neuronal genes. Key neuronal genes are aberrantly expressed in Phf3
knock-out mouse embryonic stem cells, resulting in impaired neuronal differentiation. Our
data suggest that PHF3 acts as a prominent effector of neuronal gene regulation by bridging
transcription with mRNA decay.
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Transcription is a highly regulated process of RNA Poly-merase II (Pol II) recruitment, initiation, pausing, elon-gation and termination1–3. Transcription regulation is
critical to establish and maintain cell identity, and transcription
misregulation underlies cancer and other diseases4. Transcription
elongation factors modulate Pol II pause release, backtracking,
elongation rate or processivity, and couple transcription elonga-
tion with co-transcriptional RNA processing5–17.
Transcription regulators interact with structurally defined
surfaces of the Pol II complex and with the unstructured
C-terminal domain (CTD) of the largest Pol II subunit
RPB118–20. Heptarepeats (Y1S2P3T4S5P6S7) within the Pol II CTD
undergo dynamic phosphorylation during transcription, orches-
trating the timely recruitment of regulatory factors. The early
stages of transcription are marked by Pol II phosphorylated on
Serine-5 (pS5), whereas productive elongation is characterized by
the removal of pS5 and a concomitant increase in phosphorylated
Serine-2 (pS2)18. Transcription is tightly coupled with co-
transcriptional RNA processing whereby Pol II CTD acts as a
docking site for 5’ mRNA capping, splicing, 3’end processing,
termination and mRNA export factors that recognize specific
CTD phosphorylation patterns10,21–23. Yeast and mammalian 5’
mRNA capping enzymes such as Cgt1, Pce1 and Mce1 were
shown to employ the nucleotidyltransferase (NT) domain to
directly bind pS5 within the Pol II CTD, whereas 3’end proces-
sing and termination factors such as yeast Pcf11 and mammalian
SCAF8 employ the CTD-interaction domain (CID) to directly
bind the pS2 mark on the Pol II CTD24–28. Pol II CTD undergoes
liquid-liquid phase separation (LLPS) as a means of compart-
mentalizing transcription initiation machinery in unpho-
sphorylated Pol II CTD clusters, whereas phosphorylated CTD
partitions with RNA processing factors29,30.
The PHD-finger protein 3 (PHF3) belongs to a family of
putative transcriptional regulators that includes the human
Death-Inducer Obliterator (DIDO) and yeast Bypass of Ess-1
(Bye1)31,32. This family of proteins contains two motifs found in
several transcription factors: a domain that is distantly related to
the Pol II–associated domain of the elongation factor TFIIS,
called the TFIIS-Like Domain (TLD), and a Plant Homeo
Domain (PHD)31. It also contains a Spen Paralogue and Ortho-
logue C-terminal (SPOC) domain, which has been associated
with cancer, apoptosis and transcription33. Similar to TFIIS, Bye1
binds the jaw domain of RPB1 via its TLD in vitro and
in vivo31,34. In contrast to TFIIS, Bye1 TLD does not stimulate
mRNA cleavage during transcriptional proofreading due to the
absence of the TFIIS domain III31,35. Combined deletion of the
PHD and SPOC domains abrogated Pol II binding by Bye1
in vivo, suggesting that the Bye1 TLD is necessary but not suf-
ficient to interact with Pol II34. Although PHF3 does not contain
any canonical CTD-binding domains, it was recently identified in
a mass spectrometry screen for proteins binding to phosphory-
lated GST-CTD36. However, the physiological relevance of this
interaction, and whether or how PHF3 regulates transcription,
remain unknown.
Here, we discover an unexpected interaction between PHF3
and the Pol II CTD via the SPOC domain. We show that PHF3
SPOC displays specificity towards CTD repeats phosphorylated
on S2, establishing the SPOC domain as a reader of the Pol II
CTD. Moreover, we find that PHF3 colocalizes with Pol II clus-
ters inside cells and forms condensates in vitro, which incorporate
phosphorylated CTD and Pol II. PHF3 exerts a dual regulatory
function on both Pol II transcription and mRNA stability in a
global and gene-specific manner. Neuronal genes are aberrantly
derepressed in PHF3 KO HEK293T cells, and Phf3 KO mESCs
show impaired neuronal differentiation. Overall, our data suggest
that PHF3, as a regulator of Pol II transcription and mRNA
stability via the CTD, controls a neuronal gene expression
program.
Results
PHF3 interacts with RNA polymerase II through the SPOC
domain. To explore the function of PHF3 in transcription, we
expressed FLAG-PHF3 in HEK293T cells and identified inter-
acting proteins by co-immunoprecipitation (co-IP) followed by
mass spectrometry (Fig. 1a, b and Supplementary Data 1). RPB1
ranked highest among 40 high-confidence PHF3 interactors
(Supplementary Data 1), including other regulators of Pol II
transcription elongation (SPT5, SPT6, PAF1C, FACT), as well as
RNA processing factors (Fig. 1a, b and Supplementary Data 1).
We confirmed these findings by co-IP analyses of endogenous
PHF3 tagged with GFP in HEK293T cells, due to the lack of
suitable commercially available PHF3 antibodies (Fig. 1c, d and
Supplementary Fig. 1a). Further, we found that endogenously
expressed PHF3-GFP interacted with Pol II phosphorylated on
Serines 2, 5 and/or 7 within the heptarepeats (Fig. 1d, e).
To determine which domains within PHF3 are required for
these interactions, we performed a co-IP analysis of different
FLAG-PHF3 deletion mutants expressed in HEK293T cells
(Fig. 1f). The truncation mutants localized to the nucleus and
bound chromatin, similar to full-length PHF3 (Supplementary
Fig. 1c, d). However, neither the TLD nor PHD domains were
required for the interaction between Pol II and FLAG-PHF3
(Fig. 1f), which was unexpected given that the TLD is required for
the Bye1-Pol II interaction in yeast31,34. In contrast, removal of
the SPOC domain from PHF3 completely abrogated the
interaction with Pol II, the elongation factor SPT5 and the Pol
II-associated factor PAF1 (Fig. 1f). Moreover, the isolated PHF3
SPOC domain (aa 1199–1356) was sufficient to bind phosphory-
lated Pol II (Fig. 1g).
PHF3 SPOC preferentially binds RNA Pol II CTD phos-
phorylated on Serine-2. SPOC domains display low sequence
conservation, but several amino acids within a positively charged
patch on the SPOC surface are highly conserved, including an
Arg residue and a Tyr residue (R1248 and Y1291 for PHF3 SPOC,
Fig. 2a). These residues are required for the SPOC-containing
protein SHARP (SPEN) to interact with the co-repressor complex
SMRT/NCoR37. Serine phosphorylation of the LSD motif within
SMRT or NCoR increases their binding affinity for the conserved
Arg within the SHARP SPOC domain, suggesting that the SPOC
domain is a phospho-serine binding module38,39.
Based on these observations, we hypothesized that the
positively charged surface of PHF3 SPOC binds the phosphory-
lated heptarepeats of Pol II CTD. To test this hypothesis, we
examined the binding of bacterially expressed PHF3 SPOC to
various phosphoisoforms of a CTD diheptapeptide (YSPTSPS-
YSPTSPS) in vitro (Supplementary Table 1). PHF3 SPOC did not
bind the unphosphorylated CTD diheptapeptide or CTD
phosphorylated on only one repeat (Supplementary Fig. 2a),
but phosphorylation of S2 within both repeats (2xpS2) was
sufficient to confer strong binding (Fig. 2b, c and Supplementary
Fig. 2a–f). Comparable affinity of PHF3 SPOC towards 2xpS2
(Kd= 1.6 ± 0.3 μM), 2xpS2pS7 (Kd= 0.8 ± 0.1 μM) and 2xpS2pS5
(Kd= 4.8 ± 0.3 μM), coupled with lower affinity for 2xpS5
(Kd= 20.0 ± 4.0 μM) or 2xpS7 (Kd= 26.0 ± 2.9 μM), suggested
that PHF3 SPOC preferentially binds 2xpS2 (Fig. 2b, c and
Supplementary Fig. 2a–f). The requirement of tandem pS2
phosphorylation marks for stable binding of PHF3 SPOC to Pol
II CTD is in line with genetic studies in yeast showing that the
minimal functional unit of CTD is a diheptad40,41, and with mass
spectrometry analysis of CTD phosphorylation patterns revealing
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that concurrent phosphorylations are more frequent along
adjacent heptad repeats than within the same repeat42,43.
To uncover the basis of the CTD heptapeptide-SPOC
interaction, we determined the structure of PHF3 SPOC in the
apo form (2.6 Å), and bound to 2xpS2 (2.0 Å), 2xpS2pS7 (1.75 Å)
and 2xpS2pS5 (2.85 Å) diheptapeptides (Fig. 2d–h, Supplemen-
tary Fig. 2i–m, Supplementary Table 2). The three different
2xpS2-containing peptides with comparable binding affinities
were used for structural analysis to determine whether PHF3
SPOC exclusively binds tandem pS2 marks or whether it can
concomitantly engage pS7 or pS5 as shown for yeast Rtt103
(binds pS2pS7) and human PIN1 (binds pS2pS5)44,45. Super-
imposition of PHF3 SPOC with SPOC domains from SHARP38



























































































































Pathway ID Biological process pValue
GO.0016070 RNA metabolic process 8.70E-26
GO.0010467 gene expression 2.74E-24
GO.0006351 transcription, DNA-templated 1.38E-21
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comparable to other structurally characterized SPOCs, with seven
β-strands and four helices connected with various loop regions
(Fig. 2d). The 2xpS2- and 2xpS2pS7-diheptapeptides were bound
between strands of the β-barrel and along the α1 helix, in an
extended conformation with trans isomer configuration of
prolines (Fig. 2e–h). The two phospho groups at S2 of the
diheptapeptides were electrostatically anchored by two positively
charged patches on the SPOC surface, which flank the central
hydrophobic patch (Fig. 2e–h and Supplementary Fig. 2i–m).
SPOC binding to phosphorylated serines in adjacent repeats
imposed an extended conformation on the CTD diheptapeptide
(Fig. 2e–h).
The ε-amino groups K1267 and K1309 from the first patch on
SPOC form a hydrogen bond with O1P from the N-terminal
pS2a, whereas guanidinium nitrogens from R1248 and R1297
from the second patch form hydrogen bonds with O1P and O3P
from the C-terminal pS2b (Fig. 2g, h). Consistent with these
findings, the R1248A substitution within SPOC reduced the
binding to diheptapeptides containing pS2 more than 10-fold
in vitro and reduced the interaction between PHF3 and Pol II in
cells (Fig. 2b, c and Supplementary Fig. 2b–g). pS7 within the
2xpS2pS7 diheptapeptide did not form contacts with SPOC, as S7
was projected away from the SPOC surface (Fig. 2h and
Supplementary Fig. 2i). I1249 and V1300 from the hydrophobic
patch of SPOC form contacts with Y1b, and T1253, Y1257 and
Y1312 form a hydrophobic pocket for P6a (Fig. 2g, h).
Hydrophobic contacts with Y1b and P6a are critical for
establishing the register of the CTD to ensure specific anchoring
of pS2 marks in the basic patches. All of these residues within
PHF3 SPOC are generally conserved across species, as well as
with DIDO SPOC (Fig. 2a, i and Supplementary Fig. 2h).
Fluorescence correlation spectroscopy (FCS) showed a 1:1 stoi-
chiometry of the SPOC:pS-diheptapeptide interaction (Supple-
mentary Fig. 3a–c). Mass photometry showed that full length
PHF3 forms monomers in vitro (Supplementary Fig. 3d),
suggesting that one PHF3 molecule engages two pS2 CTD
repeats through its SPOC domain. Taken together, our data show
that the PHF3 SPOC domain is a previously unrecognized Pol II
CTD-binding domain that preferentially recognizes the elongat-
ing form of Pol II phosphorylated on S2.
PHF3 drives liquid-liquid phase separation of phosphorylated
Pol II CTD. Phosphorylated CTD was shown to localize inside
phase-separated condensates formed by splicing factors, which
bind pS2 CTD30. Thus we tested whether PHF3 and its SPOC
domain can modulate LLPS of phosphorylated Pol II CTD. CTD
was phosphorylated with the DYRK1A kinase, which pre-
ferentially targets S247 (Supplementary Fig. 4a). Unpho-
sphorylated mEGFP-CTD formed condensates (median area
2.4 µm2) at physiological salt concentration (150 mM NaCl),
which were abrogated by 1,6-hexanediol (Fig. 3a, b and Supple-
mentary Fig. 4b–d), according to previous findings29. CTD
phosphorylation impaired condensate formation due to
electrostatic repulsion (median area 1.6 µm2) (Fig. 3a, b and
Supplementary Fig. 4b–d).
The SPOC domain alone did not form condensates, but
colocalized within pS2 CTD condensates (Fig. 3a, b, Supplemen-
tary Fig. 4b–f). Unlike the isolated SPOC domain, full length
PHF3 formed condensates (median area 5.2 µm2) that were
abrogated in the presence of 1,6-hexanediol, which interferes with
hydrophobic interactions (Fig. 3a, b and Supplementary
Fig. 5a–c). PHF3 condensates were larger at a higher salt
concentration, confirming that PHF3 LLPS is primarily driven by
hydrophobic interactions (Supplementary Fig. 5a–c). Phosphory-
lated CTD partitioned into PHF3 condensates and modulated
their size in a salt-dependent manner (Fig. 3a, b and
Supplementary Fig. 5a–c). PHF3-phCTD condensate size
decreased with higher salt concentration due to interference with
electrostatic interactions between PHF3 SPOC and phCTD
(Supplementary Fig. 5a–c). Our results suggest that PHF3
condensates are primarily formed through hydrophobic interac-
tions, while PHF3-phCTD condensation is additionally modu-
lated through electrostatic interactions.
Finally, we tested whether PHF3 can drive LLPS of the Pol II
complex. DYRK1A-phosphorylated Pol II (Supplementary
Fig. 5d) did not undergo LLPS but partitioned into PHF3
condensates (Fig. 3a, b). PHF3-phPol II condensates were five
times larger than PHF3 condensates (median area 27.8 µm2),
suggesting that multivalent interactions between PHF3 and phPol
II promote the assembly of large condensates. PHF3 showed
highest mobility within PHF3-phPol II condensates based on
fluorescence recovery after photobleaching (FRAP), indicating
that PHF3-phPol II interaction promotes PHF3 diffusion
(Supplementary Fig. 5e, f).
PHF3 colocalizes in Pol II clusters and travels with Pol II
across the length of genes. The physiological relevance of Pol II
CTD LLPS is to drive Pol II nuclear clustering as a means of
compartmentalizing transcription from RNA processing29,30.
Super-resolution imaging revealed that PHF3 colocalizes within
Pol II clusters in cells (Fig. 3c, d). To examine genome-wide
colocalization between PHF3 and Pol II, we performed ChIP-seq
of PHF3-GFP, Pol II pS2, Pol II pS5 and Pol II pS7. ChIP-seq
analysis showed that PHF3 tracked with Pol II across the length
of genes, with increasing strength from TSS (transcription start
site) to pA (polyadenylation sites) (Fig. 3e and Supplementary
Data 2). Additionally, higher PHF3 occupancy coincided with
higher Pol II occupancy, particularly along the gene bodies
(Supplementary Fig. 6), and with higher transcription levels
according to single base-resolution, precision nuclear run-on and
sequencing (PRO-seq) (Fig. 3f). Overall, these data indicate that
PHF3 travels with the Pol II transcription machinery.
PHF3 regulates gene expression. To address the functional
relevance of PHF3 colocalization with Pol II, we used the uridine
analog EU (5-ethynyl uridine) coupled to Alexa Fluor to detect
Fig. 1 PHF3 interacts with RNA polymerase II via the SPOC domain. a GeneMANIA135 interaction map of the PHF3 interactome. b Gene ontology
biological processes of the PHF3 interactome revealed by mass spectrometry. c Expression levels and nuclear localization of PHF3-GFP in the endogenously
tagged HEK293T cell line revealed by Western blotting with anti-PHF3 and fluorescence microscopy. Scale bar= 10 μm. The experiment was performed
once. d PHF3-GFP was immunoprecipitated using anti-GFP. Pol II phosphoisoforms, as well as transcription regulators SPT5, SPT6, PAF1, and FACT
complex (SPT16 and SSRP1) were detected in the eluates. The experiment was performed once. e Endogenous Pol II phosphoisoforms were
immunoprecipitated from PHF3-GFP cells and PHF3-GFP was detected in the eluates. The experiment was performed once. f Anti-FLAG
immunoprecipitation of FLAG-PHF3 deletion mutants. Pol II does not co-immunoprecipitate in the absence of the PHF3 SPOC domain. The experiment was
performed four times. Representative blots are shown. g Anti-FLAG immunoprecipitation of the FLAG-SPOC domain shows interaction with Pol II. The
experiment was performed once.
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Fig. 2 PHF3 SPOC binds pS2 CTD peptides in vitro. a Structure-based alignment of SPOC domains from PHF3 (6Q2V), SHARP (2RT5), and FPA (5KXF).
Conserved residues are marked with an asterisk. b, c Fluorescence anisotropy (FA) measurement of the binding of b, 2xpS2 and c, 2xpS2pS7 FAM-labeled
CTD peptides to PHF3 SPOCWT or R1248A mutant. Normalized fluorescence anisotropy is plotted as a function of protein concentration (n= 3). The data
were normalized for visualization purposes and the experimental isotherms were fitted to one site saturation with non-specific binding model. d Overlay of
SPOC structures from PHF3 (6Q2V), SHARP (2RT5) and FPA (5KXF) showed an average RMSD of 2.75 Å over 149 aligned Cα atoms between PHF3 and
SHARP SPOC, and average RMSD of 1.94 Å over 123 aligned Cα atoms between PHF3 and FPA SPOC. e 2xpS2 CTD peptide binds two positively charged
patches (Patch 1 and 2) on the surface of PHF3 SPOC. The color coded electrostatic surface potential of SPOC was drawn using the Adaptive Poisson-
Boltzmann Solver package within PyMol. The electrostatic potential ranges from −5 (red) to +5 (blue) kT/e. The N- and C-termini of the peptide are
indicated and always shown in the same orientation. f 2 Fo − Fc electron density map of pS2 peptide contoured at the 1.5σ level. CTD peptide sequences
used for X-ray structures correspond to those used in binding assays. The residues of the CTD diheptapeptide that are visible in the structure are indicated
in bold. CTD peptides used for X-ray structures had the same sequence as for the binding assays but were not fluorescently labeled. g, h Hydrogen bonding
interactions between g, 2xpS2 and h, 2xpS2pS7 CTD peptides and PHF3 SPOC. SPOC monomer binds two phosphorylated S2 groups on the CTD peptides.
SPOC residue labels from two positively charged patches are colored blue and the patches are contoured with dashed circles. i Evolutionary conservation of
PHF3 SPOC residues projected onto the 2xpS2 co-structure using the ConSurf server. Residues are colored by their conservation grades with maroon
showing the highest and turquoise the lowest degree of conservation. Two positively charged patches (Patch 1 and 2) are indicated.
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newly synthesized RNA. Super-resolution imaging revealed reduced
signal in Pol II clusters that overlap with PHF3 (Fig. 4a, b), indicating
that PHF3 may be associated with reduced transcriptional activity. To
further elucidate the function of PHF3 in transcription, we used
CRISPR/Cas9 to generate PHF3 knock-out HEK293T cells (PHF3
KO) and HEK293T cells lacking the SPOC domain (PHF3 ΔSPOC)
(Supplementary Fig. 7). PHF3 ΔSPOC was expressed at lower levels
compared to PHF3 WT suggesting that removal of the SPOC
domain may reduce protein stability (Supplementary Fig. 7c). We
initially assessed the effect of PHF3 loss or SPOC deletion by mon-
itoring incorporation of EU during transcription by confocal
microscopy or FACS (Fig. 4c–e and Supplementary Fig. 8). PHF3 KO
and PHF3 ΔSPOC cells showed significantly higher EU levels than
WT cells (Fig. 4c–e), suggesting increased transcript levels.
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To investigate the changes in RNA levels genome-wide, we
performed RNA-seq to measure mature transcripts, and PRO-seq
to measure nascent transcripts (Fig. 4f–j, Supplementary Figs. 9,
10 and Supplementary Data 3). We found that mature transcript
levels were generally increased in both PHF3 KO and ΔSPOC
cells compared to WT: 620 and 638 mature transcripts were
elevated >2-fold (p-value<0.05) in PHF3 KO or ΔSPOC cells
relative to WT, with 281 (~45%) elevated in both conditions
(Fig. 4f and Supplementary Fig. 9a). In contrast, only 173 and 74
mature transcripts were downregulated >2-fold in PHF3 KO or
ΔSPOC relative to WT, with 37 downregulated in both
conditions.
Unlike mature transcripts, nascent transcripts did not show
major changes in PHF3 KO and ΔSPOC cells (Fig. 4g and
Supplementary Fig. 9b). We observed increased nascent tran-
scription of 68 and 78 genes >2-fold in PHF3 KO or ΔSPOC cells
relative to WT, with 29 elevated in both conditions. Similarly, 39
and 70 genes showed decreased transcription >2-fold in PHF3
KO or ΔSPOC cells relative to WT, with 10 reduced in both
conditions. About 10% of the mature transcripts with elevated
steady-state levels in PHF3 KO or ΔSPOC cells had a
concomitant increase in nascent transcripts (orange dots in
Fig. 4h; example of an RNA-seq/PRO-seq upregulated gene in
Fig. 4i; example of an RNA-seq upregulated gene in Fig. 4j).
Overall, these data suggest that loss of PHF3 causes a
derepression of a subset of genes, and that the binding of PHF3
to Pol II via the SPOC domain contributes to its function.
PHF3 loss results in increased Pol II stalling and reduced
elongation rate. To understand how PHF3 may regulate Pol II
transcription, we analyzed Pol II distribution in PHF3 WT, KO,
and ΔSPOC by PRO-seq and Pol II ChIP-seq (Fig. 5a, b and
Supplementary Fig. 9c, d). Metagene profiles showed a small
reduction in PRO-seq nascent transcript levels in the gene bodies
and towards polyadenylation (pA) sites (‘All genes’ in Fig. 5a and
Supplementary Fig. 9c). Pol II occupancy was elevated at TSS and
reduced along gene bodies in PHF3 KO and ΔSPOC cells relative
to WT cells (‘All genes’ in Fig. 5a). A change in Pol II occupancy
may indicate impaired pause release5,13,14,48. Pol II stalling index
(TSS reads/gene body reads)14 showed increased stalling in PHF3
KO cells based on Pol II occupancy but no difference based on
PRO-seq (‘All genes’ in Fig. 5b). The same type of analysis for
RNA-seq upregulated genes revealed increased stalling in PHF3
KO and ΔSPOC cells based on both PRO-seq and Pol II occu-
pancy (‘RNA-seq UP genes’ in Fig. 5a, b).
Considering that a change in Pol II distribution was also linked
with a change in elongation rate and that elongation factors
RECQL5, PAF1, and SCAF8 were shown to modulate elongation
rate11,15,16,49, we measured in vivo transcription elongation rate
by blocking pause release with a CDK9 inhibitor 5,6-dichloro-1-
β-D-ribofuranosyl-benzimidazole (DRB) applied for 3.5 h, fol-
lowed by DRB washout to allow transcription for 10, 25, and
40 min (Fig. 5c). PRO-seq analysis of the front edge of waves of
nascent transcription allowed us to deduce Pol II elongation rate
(Supplementary Data 4). PHF3 loss or SPOC deletion led to a
reduction in elongation rate after 10 min (median elongation rate:
2.62 kb/min for KO, 2.66 kb/min for ΔSPOC and 3.37 kb/min for
WT) followed by a subsequent increase and leveling off by the
40 min timepoint, without having major effects on Pol II
processivity (Fig. 5d, e). Genes with reduced elongation rate
consistently showed a decrease in nascent transcript levels
revealed by PRO-seq analysis (Fig. 5f and Supplementary
Fig. 11a). Interestingly, genes with reduced elongation rate also
showed a mild tendency towards upregulation in RNA-seq in
PHF3 KO and ΔSPOC (fold change<2), indicating coupling
between reduced elongation and an increase in mature transcript
levels (Fig. 5g and Supplementary Fig. 11b). Taken together, our
data show that PHF3 globally promotes pause release and Pol II
elongation. However, its loss has little effect on nascent RNA
levels but causes an increase in mRNA levels.
PHF3 loss results in increased mRNA stability. RNA-seq and
PRO-seq analyses revealed that a subset of ~600 genes showed an
increase in mature transcripts without major alteration in nascent
transcription levels, indicating that PHF3 loss leads to increased
mRNA stability. We calculated the difference in log2 fold changes
KO/WT or ΔSPOC/WT between RNA-seq as a measure of
steady-state mRNA content, and PRO-seq as a measure of mRNA
production rate (Fig. 6a). Differences were strikingly skewed
towards positive values, indicating that the changes in the steady-
state mRNA levels are greater than the changes in transcriptional
rates (Fig. 6a). This finding strongly suggested that PHF3 reg-
ulates mRNA stability. To validate this further, we determined
mRNA half-lives by performing SLAM-seq [Thiol (SH)-Linked
Alkylation for the Metabolic sequencing of RNA]50 (Supple-
mentary Fig. 12a). Cells were pulse-labeled for 12 h with s4U (0 h
sample), followed by a chase with uridine for 6 and 12 h. The T-C
conversion rate was used to determine mRNA half-lives for genes
that showed conversion rates >0 at the 0 h timepoint and a
monotonic decrease in median conversion rates (Fig. 6b, Sup-
plementary Fig. 12 and Supplementary Data 5).
We observed a significant overall increase in mRNA half-lives
in PHF3 KO and ΔSPOC compared to WT (median half-lives:
5.948694 h for PHF3 KO, 5.970330 h for ΔSPOC and 4.837077 h
for WT; Fig. 6b). 62% genes showed increased mRNA half-lives in
both PHF3 KO and ΔSPOC (Fig. 6c), and an additional 27%
showed an increased half-life in either KO or ΔSPOC
(Supplementary Data 5). Because global SLAM-seq analysis failed
Fig. 3 PHF3 drives liquid-liquid phase separation of phosphorylated Pol II, colocalizes in Pol II clusters in cells and associates with Pol II genome-wide.
a Representative images of in vitro LLPS assays with 5 µM unphosphorylated or phosphorylated mEGFP-CTD, 5 µM mCherry-SPOC, 3 µM Alexa594-PHF3,
3 µM phosphorylated Alexa488-Pol II, 1.5 µM phosphorylated Alexa647-Pol II + 1.5 µM Alexa488-PHF3. Scale bar= 5 µm. The experiments were repeated
three times and the representative images are shown. b Quantification of condensate area (µm2). N= 556 (CTD); 64 (phCTD); 89 (phCTD+SPOC); 582
(phPol II); 480 (PHF3); 580 (PHF3+phCTD); 588 (PHF3+phPol II). Data are presented as median with interquartile range. Mann-Whitney test was used
to determine p-values (Supplementary Data 7). c Representative Airyscan high resolution images of PHF3-GFP (IF staining with rabbit anti-GFP + Alexa
Fluor 488, green) and Pol II pS2 or pS5 (Alexa Fluor 594, red). Co-localization analysis of clusters that overlap in both channels (white). Scale bar= 5 µm
or 200 nm for zoomed regions. d Quantification of the fraction of Pol II pS2 (N= 28) and Pol II pS5 (N= 23) co-localizing with PHF3. Box and whiskers plot
with error bars representing 10 and 90 percentiles are shown. Each experiment was repeated three times with comparable results. Statistics are indicated
in detail in Supplementary Data 7. e ChIP-seq analysis shows that PHF3 travels with Pol II across the length of genes. Relative enrichment of PHF3, Pol II
pS2, pS5, and pS7 on TSS-gene body region (TSS viewpoint; left panel) and gene body-pA region (pA viewpoint; right panel) for genes that showed Pol II
occupancy with the F-12 antibody (minimal gene body RPKM of 5 in F-12 ChIP-seq). f Scatter plots showing PRO-seq nascent transcription levels at gene
body relative to TSS in WT cells. Blue dots indicate PHF3-bound genes at transcription start sites (TSS, left), gene body (Body, middle) or polyadenylation
sites (pA, right).
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to capture low-expressed genes, which exhibit the strongest
upregulation in PHF3 KO and ΔSPOC (Supplementary Fig. 12d),
we applied a targeted SLAM-seq approach to specifically analyze
mRNA half-lives for INA as one of the most highly upregulated
genes in PHF3 KO and ΔSPOC. INA showed a pronounced
increase in mRNA half-life from 3.3 h in WT to 7.1 h in ΔSPOC
and 19.5 h in PHF3 KO (Fig. 6d), which was not observed for the
housekeeping gene NAT10 (Fig. 6e). Comparison of changes in
RNA-seq and SLAM-seq showed that the increase in mRNA
stability was concordant with the increase in mature transcript
levels (Fig. 6f, g). Moreover, increased mRNA stability in PHF3
KO/ΔSPOC may be coupled with reduced elongation rate, as
genes with reduced elongation rate also had longer mRNA half-
lives in PHF3 KO/ΔSPOC (Fig. 6h, i).
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Overall, our data define PHF3 as an elongation factor that
regulates different aspects of RNA biogenesis, spanning from
transcription to RNA metabolism.
PHF3 negatively regulates a small subset of genes by compet-
ing with TFIIS. The most profound changes in gene expression
following PHF3 or SPOC depletion affected a small subset of ~70
genes, which were highly upregulated at both the nascent and
mature transcript level (RNA-seq/PRO-seq upregulated, Fig. 4h).
Genes with highly elevated transcripts in PHF3 KO and ΔSPOC
are transcribed at low levels in WT cells and enriched for both the
repressive H3K27me3 mark and the active H3K4me3, as well as
pS5 (Fig. 7a, b, Supplementary Fig. 13, Supplementary Data 2).
ChIP analysis showed a decrease in H3K27me3 on these genes in
PHF3 KO and ΔSPOC cells (Fig. 7c). Accordingly, super-
resolution imaging showed reduced colocalization of Pol II with
H3K27me3 in PHF3 KO and ΔSPOC (Fig. 7d, e), suggesting that
PHF3-mediated transcriptional derepression is coupled with the
loss of Polycomb-mediated silencing. Overall, these data suggest
that Pol II is in a poised state and possibly undergoing fast
turnover at this group of genes in WT cells51,52.
Poised Pol II may experience high levels of backtracking due to
high GC content, specific promoter elements, or chromatin
configuration3,53. Backtracked polymerase is rescued by the
positive elongation factor TFIIS, which stimulates cleavage of the
nascent RNA and allows Pol II to resume transcription17,35,54,55.
Given that PHF3 harbors a TFIIS-like domain (TLD), which could
potentially displace TFIIS from Pol II, we examined TFIIS binding
profile in PHF3 WT, KO, and ΔSPOC cells by ChIP. TFIIS
occupancy was increased most prominently on genes that were
both PRO-seq and RNA-seq upregulated in PHF3 KO or ΔSPOC
and did not change on genes that were not transcriptionally
deregulated (Fig. 7f, g and Supplementary Data 2). TFIIS and the
TLD domain of the yeast PHF3 homolog Bye1 bind a similar
region on Pol II31 (Supplementary Fig. 14). To test whether PHF3
can compete with TFIIS for binding to Pol II, we used sucrose
gradient ultracentrifugation to analyze complexes formed between
Pol II-EC (elongation complex) and PHF3 in the presence of TFIIS
as a competitor, and vice versa (Supplementary Fig. 15a). We used
an inactive TFIIS mutant (TFIISM; D282A E283A) to prevent RNA
cleavage and Pol II-EC disassembly. Although TFIIS could not
displace PHF3 from Pol II-EC, PHF3 almost completely displaced
TFIIS from Pol II-EC (Supplementary Fig. 15a). These data suggest
that PHF3 competes with TFIIS for binding to Pol II in vitro.
TFIIF, which cooperates with TFIIS to rescue arrested Pol
II56,57, stabilized the association between TFIIS and Pol II but
did not prevent PHF3-mediated displacement of TFIIS (Sup-
plementary Fig. 15b). TFIIF itself was not displaced by PHF3,
nor did it outcompete PHF3 from the Pol II-EC (Supplementary
Fig. 15b), indicating that PHF3 does not compete with TFIIF.
Thus, even in the presence of TFIIF, PHF3 outcompetes TFIIS
for binding to Pol II. Furthermore, we tested whether PHF3
inhibits the function of wild-type TFIIS in a transcription assay
using an arrest template. Pol II-EC efficiently transcribed the
arrest sequence in the presence of TFIIS, but elongation was
diminished in the presence of PHF3 (Fig. 7h). PHF3 lacking the
TLD domain (PHF3 ΔTLD) did not interfere with TFIIS-
dependent elongation, confirming that the PHF3 TLD domain is
critical for competition with TFIIS (Supplementary Fig. 15c).
PHF3 TLD alone did not affect TFIIS-dependent elongation, as
the SPOC domain is required for docking PHF3 onto Pol II
(Supplementary Fig. 15d). Taken together, our results suggest
that PHF3 negatively regulates transcription of a small subset of
genes by competing with the transcription factor TFIIS and
impairing rescue of backtracked Pol II. PHF3 competition with
TFIIS explains the increase in both nascent and mature
transcripts observed for a subset of genes in the absence of
PHF3 or its SPOC domain.
PHF3 regulates neuronal gene expression and is required for
neuronal differentiation of mESCs. GO analysis of the upre-
gulated transcripts in PHF3 KO and ΔSPOC HEK293T cells
revealed an enrichment of neuronal genes (Fig. 8a and Supple-
mentary Fig. 9e, f), whereas downregulated or unaffected genes
did not show any particular functional enrichment. To con-
solidate the tissue specificity of transcriptionally upregulated
genes, we used the TissueEnrich tool58, which revealed cerebral
cortex as the only tissue with significant enrichment (Fig. 8b and
Supplementary Fig. 9g).
The neuronal genes INA and GPR50 exhibited low mRNA
levels in WT HEK293T cells, whereas loss of PHF3 or the PHF3
SPOC domain resulted in a pronounced increase in their mRNA
levels and increased occupancy of Pol II throughout the gene
(Fig. 8c and Supplementary Fig. 16). Exogenous expression of
PHF3 in PHF3 KO cells reduced the expression of INA and
GPR50 mRNAs to levels that were comparable to WT cells
Fig. 4 PHF3 negatively regulates mRNA levels. a High-resolution Airyscan imaging reveals a high degree of co-localization between Pol II pS5 and 5-EU
whereas only a small fraction of Pol II pS2 or PHF3-GFP co-localizes with 5-EU (N= 21 for pS5; N= 15 for pS2; N= 23 for PHF3). The mean EU intensity is
decreased in clusters where PHF3 and Pol II overlap compared to clusters containing only Pol II. Box and whiskers plots with error bars representing the 10
and 90 percentiles are shown. One-way ANOVA with Tukey’s multiple comparison test was performed to determine p-values (<0.0001). Each experiment
was repeated twice with comparable results. Statistics are indicated in detail in Supplementary Data 7. b Representative Airyscan high resolution images of
5-EU (yellow), PHF3-GFP (green) and Pol II pS2 or pS5 (red) and clusters of Pol II that co-localize with EU or with both EU and PHF3 (white). Scale
bar= 5 µm or 200 nm for zoomed regions. c–e PHF3 KO and ΔSPOC show increased incorporation of EU-Alexa Fluor 488 by c, fluorescence microscopy
(scale bar= 10 µm) and d, e FACS analysis. d Cell counts for each fluorescence intensity in the absence (-EU) or presence of EU (+EU). e Percentage of
cells belonging to the gated P1 fluorescent population shown in d. The following cell numbers were examined over three independent experiments:
N= 29059 (WT –EU), N= 29918 (KO –EU), N= 29847 (ΔSPOC –EU), N= 29146 (WT +EU), N= 29649 (KO +EU), N= 29771 (ΔSPOC +EU). Data are
presented as mean values ± standard deviation. One-tailed, two-sample equal variance t-test was used to determine p-values (Supplementary Data 7).
f RNA-seq analysis shows upregulation of 620 genes (red dots, fold-change>2, p < 0.05) and downregulation of 173 genes (blue dots, fold-change>2,
p < 0.05) in PHF3 KO compared to WT. Drosophila S2 cells were used for spike-in normalization. g PRO-seq analysis shows upregulation of 68 genes (red
dots, fold-change>2, p < 0.05) and downregulation of 39 genes (blue dots, fold-change>2, p < 0.05) in PHF3 KO compared to WT. Drosophila S2 nuclei
were used for spike-in normalization. Mean Pearson correlation coefficient between the samples was 0.96 (see Supplementary Fig. S10c). h Relationship
between RNA-seq and PRO-seq fold change for PHF3 KO vs WT. Genes that are upregulated in PHF3 KO in RNA-seq but not PRO-seq are indicated in
blue. Genes that are upregulated in both RNA-seq and PRO-seq are indicated in orange. i Integrative Genomics Viewer (IGV) snapshots showing RNA-seq
and PRO-seq reads for GPR50 as a typical gene with increased RNA-seq and PRO-seq in PHF3 KO and ΔSPOC cells. j IGV snapshots showing RNA-seq and
PRO-seq reads for STX1B as a typical gene with increased RNA-seq but no change in PRO-seq in PHF3 KO and ΔSPOC cells. RNA-seq was performed after
Ribo-Zero treatment of total RNA.
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(Fig. 8c). Importantly, PHF3 ΔSPOC failed to rescue the PHF3
KO phenotype (Fig. 8c).
Many of the neuronal genes that we found to be directly
repressed by PHF3, including INA59 and GPR5060, have been
implicated in different aspects of neurodevelopment. Moreover,
PHF3 expression levels were found to be reduced in glioblastoma,
the most common undifferentiated brain tumor61. To examine a
potential role for PHF3 in proper neuronal differentiation, we
used CRISPR/Cas9 to generate Phf3 KO mouse embryonic stem
cells (mESCs) (Fig. 8d and Supplementary Figs. 17 and 18). We
differentiated Phf3 KO and WT mESCs into neural stem cells
(NSCs), and subsequently into neurons or astrocytes. As
expected, NSCs derived from WT mESCs could differentiate into
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connected neuronal clumps (Fig. 8e, f). WT NSCs could also
differentiate into glial fibrillary acidic protein (GFAP)-positive
astrocytes (Fig. 8f). In contrast, although NSCs derived from Phf3
KO mESCs formed astrocytes comparable to WT NSCs, they failed
to differentiate into properly shaped and connected neurons (Fig. 8e,
f). Additionally, we found that Phf3 transcript levels were elevated in
WT NSCs relative to WT mESCs, suggesting that Phf3 expression is
regulated during neuronal differentiation (Fig. 8g). Although we
cannot completely exclude the possibility that loss of Phf3 might
affect other differentiation pathways, our findings suggest that Phf3 is
required for proper terminal differentiation of NSCs, specifically into
the neuronal lineage.
We hypothesized that loss of Phf3 triggers derepression of
specific genes that must be tightly regulated for efficient neuronal
differentiation. To test this, we analyzed Phf3 KO mESCs by
RNA-seq. Indeed, loss of Phf3 led to sustained upregulation of
several factors that are important for neuronal fate specification,
such as Ascl1, Pou3f2, Sox21, and Nestin, in mESCs, NSCs, and
neurons (Fig. 8h, Supplementary Data 6). The pioneer proneural
transcription factor Ascl1 must be tightly regulated for the
development and proliferation of NSCs, as well as for the
differentiation of progenitors along the neuronal lineage62. The
transcription factor Pou3f2 (also called Oct7 or Brn2) acts
downstream of Ascl1 and is required for the differentiation of
neural progenitor cells into functional neurons63. High levels of
the intermediate filament Nestin are also expected to interfere
with terminal neuronal differentiation64. Upregulation of the
transcription factor Sox21 induces premature expression of
neuronal markers but also inhibits terminal neuronal
differentiation65–67. Additionally, the stemness marker Sox2,
which promotes neural stemness specification and suppresses
neuronal differentiation68, was upregulated in Phf3 KO NSCs and
neurons relative to WT controls (Supplementary Fig. 17d).
Whereas neuronal factors were upregulated upon loss of Phf3,
the embryonic stemness markers Oct4 and Nanog showed
reduced expression in Phf3 KO in NSCs and neurons relative
to WT controls (Supplementary Fig. 17d). In line with the
premature expression of neural markers, Phf3 KO mESCs showed
accelerated exit from naive pluripotency compared to WT
mESCs, as observed by upregulation of Pou3f1 (Oct6), Fgf5,
Otx2, and Pax6 within the first 24 h of differentiation
(Supplementary Fig. 17e). Taken together, our data suggest that
Phf3 KO mESCs fail to differentiate into neurons due to aberrant
and precocious derepression of factors that regulate neuronal
commitment and terminal differentiation.
Discussion
Here, we established PHF3 as a Pol II regulator that couples
transcription with mRNA stability. In addition, we discovered
that PHF3 is required for proper neuronal differentiation by
preventing the precocious expression of a subset of neuronal
genes. We found that PHF3 binds to the Pol II CTD phos-
phorylated on S2 through a CTD-binding domain called SPOC.
Our study reveals that the PHF3 SPOC domain is a phospho-
serine binding module akin to SHARP SPOC. Specific recognition
of phosphorylated Serine is achieved through conserved electro-
static interactions with Arginine and Lysine residues and con-
served hydrophobic interactions that involve Tyrosine. PHF3
SPOC specifically docks onto phosphorylated Pol II CTD,
whereas SHARP SPOC engages with the phosphorylated LSD
motif of SMRT/NCoR co-repressors38,39. Despite the versatility in
binding partners, SPOC domain proteins seem to universally
regulate gene expression and differentiation. Here we showed that
PHF3 regulates neuronal gene expression and neuronal differ-
entiation, while SHARP (SPEN) was shown to regulate neural
and hematopoietic differentiation through transcriptional
repression of the Notch pathway69,70 and is crucial for Xist-
mediated X-chromosome silencing71–75. Another SPOC domain
protein, RBM15, regulates N6-methyladenosine (m6A) RNA
modification, splicing, and mRNA export, and inhibits myeloid
differentiation76–79. The yeast PHF3 homolog Bye1 negatively
regulates early stages of transcription elongation32,80, while
Arabidopsis SPOC proteins FPA and BORDER regulate 3′end
pausing and processing81,82. Future characterization of SPOC
domains from different proteins and species will address some
key questions: is the SPOC domain a universal phospho-serine
recognition module, how is the choice of binding partners
determined, and how exactly do they regulate gene expression to
ensure proper differentiation.
Specific recognition of phosphorylated Serine-2 of the Pol II
CTD classifies PHF3 SPOC as a CTD reader domain, joining the
company of (i) the CTD-interaction domain (CID) of yeast
Rtt103 (pS2pS7, pT4), Pcf11 (pS2), Nrd1 (pS5), mammalian
SCAF8 (pS2) and RPRD1A/B (pS2, pS7), (ii) the FCPH domain
of mammalian Scp1 (pS5), (iii) the nucleotidyltransferase (NT)
domain of yeast Cgt1, Pce1 and mammalian Mce1 (pS5), and (iv)
the WW domain of mammalian PIN1 (pS2pS5)22. Despite their
structural diversity, all CTD readers establish electrostatic inter-
actions with phospho-groups and hydrophobic stacking interac-
tions between CTD reader Tyrosine and CTD Proline. Different
CTD readers can have different CTD sequence recognition
requirements, which can influence CTD secondary structure22.
Our structural analysis revealed that PHF3 SPOC requires two
consecutive pS2 marks for stable binding and imposes an
extended conformation of the CTD.
While the Pol II CTD is the docking point for PHF3, this large
mammalian protein can likely establish additional contacts with
Pol II, such as through the TLD domain, which was shown to
bind the jaw-lobe domain of Pol II in the case of the yeast
homolog Bye131 (Supplementary Fig. 14). Bivalent interaction of
PHF3 with Pol II, through the Pol II jaw-lobe domain and
through the CTD, may explain the dual function of PHF3 in
transcription and mRNA stability.
How does PHF3 regulate transcription? By comparing mature
(RNA-seq) and nascent (PRO-seq) transcript levels as well as Pol
II occupancy (ChIP-seq), we identified global and gene-specific
Fig. 5 PHF3 loss results in increased Pol II stalling and reduced elongation rate. a Composite analysis of PRO-seq and Pol II (F-12) ChIP-seq distribution
and signal strength in PHF3 WT, KO, and ΔSPOC on TSS-gene body region and gene body-pA region for all genes or RNA-seq upregulated genes (fold-
change>2, p < 0.05). Mouse chromatin was used for spike-in normalization of ChIP-seq. b Stalling index analysis calculated as PRO-seq or Pol II ChIP-seq
TSS/gene body signal for all genes or RNA-seq upregulated genes (fold-change>2, p < 0.05). c IGV snapshots showing PRO-seq reads for CYB5R4 for the
elongation rate experiment. Pause release was blocked with the CDK9 inhibitor DRB for 3.5 h, followed by DRB washout to allow transcription for 10, 25,
and 40min. d Pol II elongation rate for genes >100 kb (N= 795) was calculated as the leading edge of waves of nascent transcription divided by the time
after DRB washout. Data are presented as box and whiskers plots showing the median and the interquartile range. e Processivity index for genes >100 kb
(N= 795) was calculated as log10 distal/proximal reads. Data are presented as box and whiskers plots showing the median and the interquartile range. f
Relationship between PRO-seq body fold change and t10 elongation rate (10min after DRB washout) fold change for PHF3 KO vs WT. g Relationship
between RNA-seq fold change and t10 elongation rate (10min after DRB washout) fold change for PHF3 KO vs WT.
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Fig. 6 PHF3 negatively regulates mRNA stability via the SPOC domain. a Density distribution of the differences in log2 fold changes PHF3 KO/WT or
PHF3 ΔSPOC/WT between RNA-seq and PRO-seq data. b Comparison of mRNA half-lives for 757 genes calculated from T-C conversion rates as
determined by SLAM-seq in PHF3 WT, KO, and ΔSPOC cells (n= 6). Median Spearman correlation coefficient of conversion rates for replicate samples
belonging to the same group (same genotype and timepoint) was 0.75 (see Supplementary Fig. 12c). The difference between the distributions is
statistically significant based on the one-sided Wilcoxon test [P(KO –WT)= 1.34 × 10−11, P(ΔSPOC –WT)= 2.28 × 10−11]. Statistics are indicated in detail
in Supplementary Data 7. c, Scatter plot showing correlation between half-lives in PHF3 ΔSPOC and PHF3 KO. Spearman’s correlation coefficient is
indicated. d, e Conversion rates determined from targeted SLAM-seq analysis of d, INA mRNA and e, NAT10 mRNA as a control labeled with s4U for 12 h
followed by pulse chase for 6 h and 12 h. Robust linear models were fit on the linearized form of the exponential decay equation. Y-axis shows the log2
conversion rate, shifted by the median conversion rate at t = 0 h. For INA: t1/2= 3.3 h (WT), 7.1 h (ΔSPOC), 19.5 h (PHF3 KO). For NAT10: t1/2= 3.3 h
(WT), 4.3 h (ΔSPOC), 5.0 h (PHF3 KO). f, g Relationship between RNA-seq fold change and half-life fold change for f, PHF3 KO vs WT or g, PHF3 ΔSPOC
vs WT. The majority of differentially regulated genes cluster in the top right quadrant that corresponds to mRNAs with increased steady-state levels and
half-lives. h, i Relationship between t10 elongation rate (10min after DRB washout) fold change and half-life fold change for h, PHF3 KO vs WT or i, PHF3
ΔSPOC vs WT.
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effects of PHF3 loss. Globally, PHF3 loss led to increased Pol II
stalling and reduced elongation rate, with little effect on nascent
transcript levels but with an increase in mRNA stability. A subset
of ~600 genes was strongly derepressed (>2-fold increase in
mature transcript levels), among which ~70 genes also showed a
concomitant increase in nascent transcription. While globally
PHF3 seems to act as a positive regulator of transcription
elongation and a negative regulator of RNA stability, on a small
subset of genes PHF3 exerts negative effects on both transcription
and RNA stability.
Yeast genetic studies have previously suggested competition
between the yeast homolog Bye1 and Dst1 (TFIIS) for Pol II
binding32,34 but this model has never been experimentally tested.
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with TFIIS for binding to Pol II and thereby impedes the rescue of
backtracked Pol II. Pol II backtracking is a widespread phe-
nomenon and backtracked Pol II may be particularly susceptible
to premature termination and fast turnover17, which would
explain why PHF3-regulated genes are low-expressed with low
Pol II occupancy, but have open promoters (Supplementary
Fig. 13). Our data suggest that PHF3 represses these genes by
competing with TFIIS to prevent the rescue of backtracked Pol II
and promote premature termination. Structural and biochemical
analysis of TFIIS in complex with Pol II showed that TFIIS
establishes multiple contacts with the Pol II elongation complex:
domain II-III binds the Pol II funnel and pore while domain I
binds the PAF1 complex35,83. Our biochemical experiments
showed that functional competition between PHF3 and TFIIS
requires PHF3 TLD, which occupies the same position on the Pol
II complex as TFIIS domain II. Although PHF3 displaces TFIIS
from the Pol II pore, TFIIS may remain associated with the Pol II
elongation complex through its interaction with PAF1C. In the
absence of PHF3, TFIIS binds more strongly to Pol II lobe-jaw
domain and stimulates productive elongation (Fig. 7i). Ongoing
structural work with the full-length PHF3 is expected to further
clarify the competitive binding mechanism of PHF3 with respect
to TFIIS.
How does PHF3 regulate mRNA stability? In the context of
global effects of PHF3 loss on reduced elongation, the observed
increase in mRNA stability may be a compensatory mechanism to
maintain steady-state transcript levels, also referred to as tran-
script buffering84–86. Moreover, a recent study in yeast showed
that Pol II elongation rate correlates negatively with mRNA
stability87. Negative correlation between elongation rate and
mRNA stability in PHF3 KO/ΔSPOC cells would suggest that
PHF3 is directly or indirectly involved in reinforcing the negative
feedback loop between transcription and mRNA stability. As a
direct regulator, PHF3 may cooperate or compete with elongation
and RNA processing factors that bind to the Pol II RPB4/7 stalk,
which coordinates transcription elongation with mRNA decay86.
In the context of a select number of derepressed genes, PHF3 may
regulate mRNA stability by modulating the recruitment of RNA-
binding proteins (RBPs) that were identified in the PHF3 inter-
actome and/or that associate with the Pol II CTD and regulate
RNA processing. RNA processing factors could require PHF3 for
binding to the CTD. PHF3 interacts with alternative splicing
factors such as SON, ZNF326, SAFB, RBMX, and RBM15
(Fig. 1a), but the analysis of RNA-seq data did not reveal any
major changes in splicing due to PHF3 loss. PHF3 interaction
with RBM15, which is part of the m6A writer complex, may affect
m6A RNA levels and thereby modulate mRNA stability88. Fur-
thermore, PHF3 interacts strongly with SPT6, which was shown
to regulate mRNA stability through the CCR4-NOT complex in
yeast89. CCR4-NOT promotes transcription elongation and
deadenylates mRNAs as the first step in mRNA decay. Given that
SPT6 facilitates CCR4-NOT recruitment89, PHF3 might promote
CCR4-NOT recruitment onto Pol II via SPT6 and thereby pro-
mote mRNA degradation.
Coupling between elongation and RNA processing through Pol
II CTD becomes even more relevant considering recent findings
that the CTD undergoes liquid-liquid phase separation
(LLPS)29,90. LLPS of unphosphorylated CTD may facilitate Pol II
clustering and transcriptional bursting during transcription
initiation, whereas CTD phosphorylation dissolves initiation
clusters and drives Pol II clustering with RNA processing
factors30. Our findings that PHF3 condensates capture phPol II
suggest that PHF3 may act as a bridge between pS2 CTD and
RNA processing factors. While further work will elucidate how
exactly PHF3 regulates mRNA stability, our results establish
PHF3 as a mammalian synthegradase that coordinates tran-
scription with mRNA decay91,92.
Why do genes react differently to PHF3 loss? Neuronal genes
were enriched among de-repressed genes with high levels of
nascent and/or mature transcripts. These genes are low-expressed
and Polycomb-repressed in WT cells but bear the marks of poised
Pol II (H3K4me3, Pol II pS5). Poised Pol II is found in ESCs as
well as differentiating and post-mitotic cells51. During neuronal
differentiation, poised Pol II primes neuronal transcription fac-
tors for activation whilst keeping non-neuronal genes silenced51.
PHF3 may prevent efficient TFIIS-mediated rescue of poised Pol
II from backtracking and induce premature termination. Reacti-
vation of these genes would thus be highly dependent on TFIIS,
which may be the reason for their marked derepression in PHF3
KO cells where TFIIS would gain more access to Pol II.
PHF3 shows ubiquitous expression across tissues with the
lowest expression in the brain (Supplementary Fig. 19a). Similar
expression pattern and function was demonstrated for small CTD
phosphatases (SCPs) specific for Pol II CTD pS593. SCPs are
recruited by the repressor element 1 (RE-1)–silencing transcrip-
tion factor/neuron-restrictive silencer factor (REST/NRSF)
Fig. 7 PHF3 negatively regulates a small subset of genes by competing with TFIIS. a Composite analysis of H3K27me3 distribution and signal strength in
PHF3 WT cells on TSS-gene body region for different gene categories based on RNA-seq and PRO-seq data. b Genes upregulated in PHF3 KO cells
according to RNA-seq (fold change>2) have low expression levels in WT cells as judged by nascent transcription (PRO-seq) levels at TSS. c Composite
analysis of H3K27me3 distribution and signal strength in PHF3 WT, KO, and ΔSPOC cells on TSS-gene body region for genes upregulated in RNA-seq and
PRO-seq in PHF3 KO or ΔSPOC cells (fold change>2). d Representative Airyscan high resolution images of Pol II pS2 (Alexa Fluor 594, red) and
H3K27me3 (Alexa Fluor 488, green) in PHF3 WT, KO, or ΔSPOC cells. Co-localization analysis of clusters that overlap in both channels (white). Scale
bar= 5 µm. e Quantification of the fraction of Pol II pS2 and Pol II pS5 co-localizing with H3K27me3 (pS2: N= 20 for WT; N= 14 for KO; N= 15 for
ΔSPOC. pS5: N= 18 for WT; N= 22 for KO; N= 15 for ΔSPOC.). Box and whiskers plots with error bars representing the 10 and 90 percentiles are shown.
One-way ANOVA with Tukey’s multiple comparison test was performed to determine p-values (****<0.0001; *= 0.04). Each experiment was repeated
twice with comparable results. Statistics are indicated in detail in Supplementary Data 7. f TFIIS ChIP-seq log2 fold change PHF3 KO/WT (top) or PHF3
ΔSPOC/WT (bottom) for TSS. Genes were grouped according to changes in RNA-seq and PRO-seq: downregulation in RNA-seq (fold change>2; N= 128),
upregulation in RNA-seq (fold change>2; N= 395), downregulation in RNA-seq and PRO-seq (fold change>2; N= 25), upregulation in RNA-seq and PRO-
seq (fold change>2; N= 45) or no change (N= 15868). Statistics are indicated in detail in Supplementary Data 7. Mouse chromatin was used for spike-in
normalization of TFIIS ChIP-seq. g IGV snapshots showing TFIIS ChIP-seq, PRO-seq, RNA-seq, and Pol II ChIP-seq (F-12) reads for GPR50 (left) and
GAPDH (right) as a housekeeping gene. RNA-seq was performed after Ribo-Zero treatment of total RNA. h In vitro assay monitoring Pol II elongation on an
arrest sequence in the presence of TFIIS and increasing amounts of PHF3 (left) or in the presence of PHF3 alone (right). Pol II-EC was formed using an
excess of a DNA–RNA bubble scaffold containing 5′-FAM-labeled RNA. The short elongation product seen in the ‘no NTP’ lane is due to residual ATP from
the phosphorylation reaction. The experiments were repeated three times and the representative gels are shown. i A model of PHF3-mediated regulation of
backtracking through competition with TFIIS. PHF3 represses transcription by competing with TFIIS and impeding Pol II rescue from backtracking, which
may result in premature termination.
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complex to neuronal genes and facilitate neuronal gene
repression93. However, we did not detect any correlation between
PHF3-mediated changes in gene expression and publicly available
REST binding data for HEK293 cells (Supplementary Fig. 20).
Instead, PHF3-repressed genes show enrichment of the Polycomb
H3K27me3 mark. Conditional deletion of the H3K27me3
methylatransferase Ezh2 in the developing mouse midbrain leads
to derepression of several forebrain specification genes94. Taken
together, SCPs and PHF3 may engage in two different pathways,
REST and Polycomb, which independently protect from pre-
mature or ectopic expression of neuronal genes95,96.
During neuronal differentiation of mESCs, Phf3 fine-tunes
expression of neuronal genes to ensure their timely and adequate
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undergo neuronal differentiation, implying that PHF3 is required
for neuronal development. Indeed, a Phf3 KO mouse generated by
the International Mouse Phenotyping Consortium (IMPC) exhibits
neuronal dysfunction in the form of impaired auditory brainstem
response and impaired startle reflex (www.mousephenotype.org).
Intriguingly, Phf3 loss had no effect on astrocyte differentiation.
Based on the Allen brain cell atlas as the most comprehensive
database of expression profiles from human and mouse brain cell
types97,98 we observed that PHF3 is not expressed in non-neuronal
cell types such as astrocytes, oligodendrocytes, endothelial cells and
microglia (Supplementary Fig. 19b, c). This may explain why Phf3
loss had no effect on astrocytes.
PHF3 function in the regulation of transcription and mRNA
stability may be important beyond development. PHF3 was
identified as an autism-risk gene99 due to deletion mutations in
the linker region between its TLD and SPOC domain resulting in
a frameshift and premature termination, producing a SPOC-less
protein. This illustrates how the SPOC domain is essential for the
function of PHF3, in accordance with our findings whereby PHF3
SPOC deletion phenocopies PHF3 knock-out. Moreover, PHF3
expression levels were found to be significantly downregulated in
glioblastoma61, while ASCL1, POU3F2, and SOX2, which were all
derepressed in Phf3 KO cells, have been implicated in the
maintenance and tumorigenicity of glioblastoma100,101. Our data
suggest that PHF3 downregulation may drive glioblastoma via
derepression of transcription factors that regulate neuronal
differentiation.
Methods
Cell lines and cell culture. HEK293T cells were grown in Dulbecco’s Modified
Eagle’s Medium (DMEM 4.5 g/L glucose) (Sigma) supplemented with 10% fetal
bovine serum (Sigma), 1% L-glutamine (Sigma), 1% penicillin-streptomycin
(Sigma) under 5% CO2 at 37 °C. mESCs were cultured on 0.2% gelatin coated
plates in ES-DMEM medium supplemented with LIF and 2i102. To generate
CRISPR/Cas9 PHF3 KO, gRNA targeting exon 3 was cloned between BbsI sites
under the U6 promoter in the plasmid encoding Cas9-EGFP (pX458)103. gRNA
sequence for human PHF3 was 5′-TGATACTAGTACTTTTGGAC-3′ and for
mouse Phf3 5′-ATTCGGGTTCCTCGGCCGTC-3′ (Supplementary Table 4). After
48 h of transfection with polyethylenimine (PEI; Polysciences), GFP-positive
HEK293T cells were FACS-sorted and allowed to recover in culture for 4–7 days.
Cells were subsequently FACS-sorted and GFP-negative cells were seeded 1 cell/
well in 96-wells plates. After 14 to 20 days, surviving clones were expanded in
culture, genomic DNA was isolated and PCR-amplified Cas9 target region was
sequenced. To generate CRISPR/Cas9 Phf3 KO in mESCs, Rex1GFPd2::Cas9 (RC9)
ES cells were used that carry a destabilized GFP-reporter for Rex1-expression and a
stably expressed Cas9 transgene integrated into the Rosa26 locus. ES cells were co-
transfected with 0.5 µg gRNA-expressing plasmid and 0.1 µg of dsRed expressing
plasmid. After 2 days dsRed-positive cells were FACS-sorted and plated at clonal
density into 60 mm TC-dishes. After 7 days colonies were picked and expanded in
96-well plates. To identify KO clones, genomic DNA was isolated and PCR-
amplified Cas9 target region was sequenced. To generate CRISPR/Cas9 endogen-
ously GFP-tagged PHF3, two gRNAs targeting 3′ PHF3 terminus were designed
(5′-CAGTGTGGTCCCTATCTTTG-3′ and 5′-TAAAATTTGCAGGCTGCTTC-
3′) and cloned into the plasmid pX335 encoding Cas9 nickase104. Plasmid-borne
repair template consisted of EGFP-P2A-puromycin flanked by 1.5 kb sequences
homologous to the targeted genomic region. HEK293T cells were transfected with
2 µg of each of the plasmids encoding Cas9 nickase and one of the two gRNAs and
4 µg of the repair template. Two weeks after transfection, GFP positive cells were
sorted by FACS. Two days after the sorting 0.5 µg/mL puromycin was added to the
culture medium. After 1–2 weeks, surviving colonies were picked and expanded,
genomic DNA was extracted and positive clones were identified by PCR. To
generate CRISPR/Cas9 PHF3 ΔSPOC, one gRNA target site on either side of the
SPOC domain was selected in such a way that the PAMs are within the deleted
fragment (5′-TGGCTCGATTGAACTTCATC-3′ and 5′-GGTCCATCAAAAGG-
CACAAG-3′). A 150 bp ssDNA repair template was designed which introduces an
XhoI restriction site at the junction of the two breaks without shifting the reading




HEK293T cells were electroporated with 10 µg of purified Cas9, 12 µg of each
in vitro transcribed gRNA and 4 µM repair template. Genomic DNA from the
clones was PCR-amplified to check for the deletion of 4.5 kb and digested with
XhoI to ensure that the repair template was used for homologous recombination-
mediated repair. To generate stable cell lines expressing mCherry-PHF3 constructs,
HEK293T PHF3 KO cells were transfected with 2 μg of plasmid and PEI in 6-well
plates. After 48 h, half of the cells were transferred to 10 cm dishes and grown in
medium supplemented with 0.25 µg/mL of puromycin. After 2–3 weeks, surviving
colonies were picked using glass cylinders and monoclonal populations were
expanded in culture. Positive clones were validated by Western blot.
Constructs. Human PHF3 was amplified from HEK293T cDNA and cloned into
CMV10 N3XFLAG (Sigma) between NotI and XbaI. PHF3 truncation constructs
were generated by tripartite ligation of BsaI-flanking fragments according to the
Golden Gate cloning principle105. PHF3 and ΔSPOC constructs used for com-
plementation were cloned into mCherry IRES puromycin vector (Clontech)
between AgeI and NotI. Site-directed mutagenesis was performed according to the
FastCloning protocol106. For bacterial expression, PHF3 SPOC domain
(1199–1356aa) and PHF3 TLD (924–1046aa) were cloned into pET M11 between
NcoI and XhoI for N-terminal His6 fusion. PHF3 SPOC was additionally cloned
into pET Duet 6xHis-TEV-mCherry between SacI and NotI. For insect cell
expression, PHF3 was cloned into pFB32 for N-terminal His6 fusion and
C-terminal Strep fusion. TFIIS mutant (TFIISM) was generated by site-directed
mutagenesis to introduce D282A E283A mutations in pOPINB TFIIS for bacterial
expression. pK10R7Sumo-3C TFIIF was generated by amplifying RAP74 and
RAP30 from HEK293T cDNA; RAP74 was cloned between BamHI and NotI for
N-terminal SUMO-His10 fusion, RAP30 was cloned between NdeI and KpnI.
Codon optimized mEGFP-CTD was kindly provided by Marek Sebesta.
Protein purification. SPOC and TLD were expressed in E. coli Rosetta2 (DE3) cells
(Novagen) and purified by affinity chromatography using HisTrap HP column (GE
Healthcare) equilibrated in 25 mM Tris-Cl pH 7.4, 500 mM NaCl, 20 mM imida-
zole, followed by TEV cleavage of the His6 tag and size exclusion chromatography
using Sephacryl S-200 (GE Healthcare) equilibrated in 25 mM Tris-Cl pH 7.4,
25 mM NaCl and 1 mM DTT. TFIIS or TFIISM were expressed in E. coli Rosetta2
Fig. 8 PHF3 regulates neuronal gene expression and neuronal differentiation of mouse embryonic stem cells (mESCs). a GO analysis of genes
upregulated in PHF3 KO HEK293T cells according to RNA-seq shows enrichment of genes involved in neurogenesis. GSEA Biological processes tool was
used. b TissueEnrich analysis shows the enrichment of cerebral cortex among transcriptionally upregulated genes in PHF3 KO. TissueEnrich analyses the
enrichment of a particular gene set in the tissue specific expression profiles provided by the GTEx transcriptional compendium (https://www.gtexportal.org/
home/faq#citePortal). The y-axis shows the -log10 of Benjamini–Hochberg corrected p-value. c RT-qPCR analysis of INA and GPR50 mRNA levels in PHF3
WT and PHF3 KO HEK293T cells with stable integration of mCherry empty vector, and KO-complemented cell lines stably expressing mCherry-PHF3 wild-
type or ΔSPOC. Four biologically independent experiments were performed. Data are presented as mean values ± standard deviation. The bars represent
average expression from different clones as biological replicates. A t-test was performed by comparing expression levels with WT (violet asterisk) and KO
(green asterisk). d CRISPR/Cas9 Phf3 knock-out in mESCs shows complete loss of protein by Western blotting. The experiment was performed once. e
Quantification of beta III tubulin (TuJ1)-positive neuronal clump formation in Phf3 WT and KO cells after 7 or 14 days of neuronal differentiation. Neuronal
clumps represent agglomerates of cells connected with Tuj1-positive cell projections. Four biologically independent experiments were performed. Data are
presented as mean values ± standard deviation. f Representative immunofluorescence images of TuJ1-stained neurons and glial fibrillary acidic protein
(GFAP)-stained astrocytes. Scale bar= 40 μm. The experiment was performed four times. g Phf3 expression levels in embryonic stem cells (ESCs), neural
stem cells (NSCs) and neurons determined by RT-qPCR. Four biologically independent experiments were performed. Data are presented as mean
values ± standard deviation. h Comparison of expression levels of different neuronal markers between Phf3 WT and KO ESCs, NSCs, and neurons by RT-
qPCR. Four biologically independent experiments were performed. Data are presented as mean values ± standard deviation. One-tailed, two-sample equal
variance t-test was used to determine p-values in c, e, g, h. P-values are indicated in Supplementary Data 7.
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(DE3) cells (Novagen) and purified by affinity chromatography using HisTrap HP
column (GE Healthcare) equilibrated in 25 mM Tris-Cl pH 7.4, 500 mM NaCl,
20 mM imidazole, and by size exclusion chromatography using Sephacryl S-200
(GE Healthcare) equilibrated in 5 mM Hepes pH 7.25, 100 mM NaCl, 10 µM ZnCl2
and 10 mM DTT. TFIIF (RAP74/RAP30) was expressed in E. coli Rosetta2 (DE3)
cells (Novagen) and purified by affinity chromatography using HisTrap HP column
(Ge Healthcare) equilibrated in 25 mM Tris-Cl pH 7.4, 500 mM NaCl, 20 mM
imidazole, followed by 3 C cleavage of the SUMO-His10 tag, cation exchange
chromatography using HiTrap SP column (GE Healthcare) equilibrated in 50 mM
Hepes pH 7, 150 mM KCl, 10% glycerol and 2 mM DTT, and by size exclusion
chromatography using Sephacryl S-200 (GE Healthcare) equilibrated in 20 mM
Hepes pH 7.5, 100 mM NaCl, 10% glycerol and 2 mM DTT. mEGFP-CTD was
expressed in E. coli Rosetta2 (DE3) cells and purified by affinity chromatography
using Ni-NTA beads equilibrated in 20 mM Tris-Cl pH 7.4, 500 mM NaCl, 20 mM
imidazole, 10% glycerol in the presence of protease inhibitors, followed by size
exclusion chromatography using Superdex 75 (GE Healthcare) equilibrated in
20 mM Hepes pH 7.4, 250 mM NaCl, 10% glycerol and 1 mM TCEP. PHF3 was
expressed from the EMBacY bacmid in Sf9 cells with an N-terminal His-tag and a
C-terminal Strep-tag. PHF3 was purified by affinity chromatography using HisTrap
FF column (GE Healthcare) equilibrated in 50 mM Tris-Cl pH 8, 300 mM NaCl,
0.5 mM TCEP, 20 mM imidazole, followed by anion exchange chromatography
using HiTrap ANX (high sub) FF column (GE Healthcare) equilibrated in 50 mM
Tris-Cl pH 8, 100 mM NaCl, 0.5 mM TCEP, 10% glycerol, and size exclusion
chromatography using Superose 6 (GE Healthcare) equilibrated in 50 mM Tris-Cl
pH 8.0, 300 mM NaCl, 0.5 mM TCEP. Pol II was purified from pig thymus, as
previously described107. Pig thymus was sourced from animals approved for food
consumption through an officially approved facility in Sieghartskirchen, Lower
Austria. PHF3 was labeled with Alexa Fluor 488 or 594, while Pol II was labeled
with Alexa Fluor 647 Conjugation Kit (Fast)—Lightning-Link (Abcam) according
to the manufacturer’s instructions and purified over a Superdex 200 Increase 3.2/
200 column (GE Healthcare).
Immunoprecipitation. For immunoprecipitation of exogenously expressed FLAG-
PHF3 constructs, a 10 cm dish of transfected HEK293T cells was used. Cells were
harvested 48 h after transfection and lysed in lysis buffer (50 mM Tris-Cl pH 8,
150 mM NaCl, 1% Triton, 1× protease inhibitors, 2 mM Na3VO4, 1 mM PMSF,
2 mM NaF, 50 units/mL benzonase and 1 mM DTT) for 1 h at 4 °C. 10% of the
cleared lysate was kept as input and the rest was incubated for 2 h on a rotating
wheel at 4 °C with anti-FLAG M2 magnetic beads (Sigma). For Pol II IP, Protein G
Dynabeads (Invitrogen) were washed twice with TBS and incubated with 5 μg of
mouse anti-FLAG M2 (Sigma), rabbit anti-pS2 Pol II (Abcam ab5095), mouse anti-
pS5 Pol II 4H8 (Abcam ab5408), rat anti-pS7 Pol II clone 4E12 (Millipore) or
mouse anti-Pol II clone F-12 (Santa Cruz) antibodies for 1 h on a rotating wheel at
room temperature. Beads were washed twice with TBS and cleared lysates were
added for immunoprecipitation on a rotating wheel at 4 °C ON. For immuno-
precipitation of endogenously tagged PHF3-GFP, two 15 cm dishes were used for
each cell line. Cells were harvested and lysed in lysis buffer (as above but without
DTT). The lysates were incubated on a rotating wheel at 4 °C ON with rabbit anti-
GFP (Abcam ab290) antibody. The samples were added to protein G Dynabeads
(Invitrogen) and incubated on a rotating wheel at 4 °C for 6 h. Beads were sub-
sequently washed three times with TBS and immunoprecipitated proteins were
eluted twice with 0.1 M glycine pH 2 and neutralized with Tris-Cl pH 9.2. For
Western blot, 2% of the input and 20% of the eluate were loaded for each sample.
Western blots were analyzed using Image Lab 6.0.1 (Biorad). For mass spectro-
metry analysis of FLAG-PHF3 or Pol II interactome, immunoprecipitations were
performed as described above and samples were processed for on beads digestion.
Mass spectrometry. Beads were eluted three times with 20 µL 100 mM glycine
and the combined eluates were adjusted to pH 8 using 1M Tris-HCl pH 8. Dis-
ulfide bonds were reduced with 10 mM DTT for 30 min before adding 25 mM
iodoacetamide and incubating for another 30 min at room temperature in the dark.
The remaining iodoacetamide was quenched by adding 5 mM DTT and the pro-
teins were digested with 300 ng trypsin (Trypsin Gold, Promega) overnight at
37 °C. The digest was stopped by addition of 1% trifluoroacetic acid (TFA), and the
peptides were desalted using C18 Stagetips. NanoLC-MS analysis was performed
using the UltiMate 3000 HPLC RSLC nano system (Thermo Scientific) coupled to a
Q Exactive mass spectrometer (Thermo Scientific), equipped with a Proxeon
nanospray source (Thermo Scientific). For FLAG-PHF3 IP samples, peptides were
loaded onto a trap column (PepMap C18, 5 mm × 300 μm ID, 5 μm particles, 100 Å
pore size; Thermo Scientific) followed by the analytical column (PepMap C18,
500 mm × 75 μm ID, 3 μm, 100 Å; Thermo Scientific). The elution gradient started
with the mobile phases: 98% A (water/formic acid, 99.9/0.1, v/v) and 2% B (water/
acetonitrile/formic acid, 19.92/80/0.08, v/v/v), increased to 35% B over the next
120 min followed by a 5-min gradient to 90% B, stayed there for 5 min and
decreased in 5 min back to the gradient 98% A and 2% B for equilibration at 30 °C.
The Q Exactive mass spectrometer was operated in data-dependent mode, using a
full scan followed by MS/MS scans of the 12 most abundant ions. For peptide
identification, the.RAW-files were loaded into Proteome Discoverer (version
1.4.0.288, Thermo Scientific). The resultant MS/MS spectra were searched using
Mascot 2.2.07 (Matrix Science) against the Swissprot protein sequence database,
using the taxonomy human. The peptide mass tolerance was set to ±5 ppm and the
fragment mass tolerance to ±0.03 Da. The maximal number of missed cleavages
was set to 2. The result was filtered to 1% FDR using Percolator algorithm inte-
grated in Proteome Discoverer108. For Pol II IP samples, a pre-column for sample
loading (Acclaim PepMap C18, 2 cm × 0.1 mm, 5 μm, Thermo Scientific), and a
C18 analytical column (Acclaim PepMap C18, 50 cm × 0.75 mm, 2 μm, Thermo
Scientific) were used, applying a segmented linear gradient from 2 to 35% and
finally 80% solvent B (80% acetonitrile, 0.1% formic acid; solvent A 0.1% formic
acid) at a flow rate of 230 nL/min over 120 min. Eluting peptides were analyzed on
a Q Exactive HF-X Orbitrap mass spectrometer (Thermo Scientific), which was
coupled to the column with a customized nano-spray EASY-Spray ion-source
(Thermo Scientific) using coated emitter tips (New Objective). The mass spec-
trometer was operated in data-dependent acquisition mode (DDA), survey scans
were obtained in a mass range of 375–1500 m/z with lock mass activated, at a
resolution of 120k at 200 m/z and an AGC target value of 3E6. The 8 most intense
ions were selected with an isolation width of 1.6 m/z, fragmented in the HCD cell at
27% collision energy and the spectra recorded for max. 250 ms at a target value of
1E5 and a resolution of 30k. Peptides with a charge of +1 or >+6 were excluded
from fragmentation, the peptide match feature was set to preferred, the exclude
isotope feature was enabled, and selected precursors were dynamically excluded
from repeated sampling for 20 s. Raw data were processed using the MaxQuant
software package (version 1.6.0.16;109) and the Uniprot human reference proteome
(July 2018, www.uniprot.org) as well as a database of most common contaminants.
The search was performed with full trypsin specificity and a maximum of three
missed cleavages at a protein and peptide spectrum match false discovery rate of
1%. Carbamidomethylation of cysteine residues were set as fixed, oxidation of
methionine, phosphorylation of serine, threonine, and tyrosine, and N-terminal
acetylation as variable modifications.
Analysis of mass spectrometry data. For the analysis of the PHF3 interactome
(FLAG-PHF3 IP), SAINT-MS1 was used as a statistical tool to determine the
probability of protein–protein interactions110. Prior to analysis with SAINT-
MS1110 the label-free quantification data were cleaned by removing bait and
common laboratory contaminants111. The control (empty vector) was used
simultaneously to estimate the parameters of the false interaction probability dis-
tributions. SAINT-MS1 was run for each method and fraction separately with 5000
and 10000 burn-in and sampling iterations, respectively. Protein areas were nor-
malized to obtain a median protein ratio of one between samples. Fold changes
were calculated based on these normalized protein areas. For the analysis of dif-
ferential Pol II interactome between PHF3 WT and KO cells, label-free quantifi-
cation the “match between runs” feature and the LFQ function were activated in
the MaxQuant software package109. Downstream data analysis was performed
using the LFQ values in Perseus (version 1.6.2.3;109). Mean LFQ intensities of
biological replicate samples were calculated and proteins were filtered for at least
two quantified values being present in the three biological replicates. Missing values
were replaced with values randomly selected from a normal distribution (with a
width of 0.3 and a median downshift of 1.8 standard deviations of the sample
population). To determine differentially enriched proteins we used the LIMMA
package in R (version 3.5.1.) and applied the Benjamini-Hochberg correction for
multiple testing to generate adjusted p-values.
Fluorescence anisotropy (FA). All measurements were conducted on a
FluoroMax-4 spectrofluorometer (Horiba Jobin-Yvon). The instrument was
equipped with a thermostated cell holder with a Neslab RTE7 water bath (Thermo
Scientific). The system was operated by FluorEssence software (version 2.5.3.0 and
V3.5, Horiba Jobin-Yvon). All measurements were performed at 20 °C in 25 mM
Tris-Cl pH 8, 25 mM NaCl, 1 mM DTT with the exception of measurements in
Supplementary Fig. 2f where 25 mM and 100mM NaCl buffer conditions were
compared. CTD peptides were labeled N-terminally with 5,6-carboxyfluorescein
(FAM λex= 467 nm, λem= 517 nm; Clonestar) (Supplementary Table 1). 10 nM
CTD peptide (in a volume of 1.4 ml) was titrated with increasing amounts of SPOC
protein. Each data point is an average of three measurements. The binding iso-
therms were generated by non-liner regression analyses with the software package
GraphPad Prism 7 (GraphPad Software, La Jolla).
Fluorescence correlation spectroscopy (FCS). In total 0.2 mg of lyophilized
2xpS2 and 2xpS2pS5 peptides (Clonestar) were dissolved in 30 µl DMSO (Sigma-
Aldrich). One equivalent of Atto-488 NHS ester (Atto-tec GmbH) was added to
three equivalents of peptide in DMSO followed by five equivalents of DIPEA
(Sigma-Aldrich) and incubated for 16 h at room temperature protected from light.
The reaction mixture was diluted to 50% (v/v) DMSO with water and purified by
reverse-phase HPLC on a C18 column (Agilent Technologies) using a 10–70%
gradient of acetonitrile + 0.1% TFA to water+ 0.1% TFA over 16 min, followed by
flushing at 90% acetonitrile +0.1% TFA for 2 min. The desired fractions were
lyophilized and stored at −20 °C. A ConfoCor 2 spectrofluorimeter (Carl Zeiss-
Evotec) equipped with an air-cooled Argon-laser (LASOS Lasertech GmbH;
intensity 70 μW) and a water immersion objective (C-Apochromat 63×/1.2W
Corr) was used for monitoring changes in diffusion behavior due to binding of
15 nM labeled 2xpS2 or 2xpS2pS5 peptide to dilution series of 40–0.2 µM of SPOC.
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All FCS measurements were performed in a 1536-well glassplate (Greiner Bio-One)
and a sample volume of 5 µL at 20 °C. The diameter of the pinhole was set to 35 μm
and the confocal volume was calibrated using 4 nM of Atto 488 dye (Dtrans= 4.0
× 10−10 m2 s−1). Intensity fluctuations were recorded by an avalanche photodiode
(SPCM-CD 3017) in photon counting mode over a time period of 15 s and
repeated 8 times for each sample. The normalized autocorrelation function G(τ)
describes the observed fluctuations of the fluorescence intensity δF(t) from the
mean intensity at any time compared to fluctuations at time t+ τ. It is given by
GðτÞ ¼ 1þ hδFðtÞδFðt þ τÞihFi2
where the angular brackets represent the ensemble average, 〈F〉 denotes the mean
intensity, and τ is known as the delay or correlation time interval over which the
fluctuations are compared. For a single diffusing species of Brownian motion in a
3D Gaussian confocal volume element with half axes ωxy and ωz, the auto-
correlation function G(τ) is defined by










where N is the number of particles, τD ¼
ωxy
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4D , τD being the molecular diffusion time of
the excited fluorophores moving in a three-dimensional confocal volume through an
axial (z) to radial (xy) dimension, and D the diffusion coefficient [cm2/s]. Evaluation of
the autocorrelated curves was performed with the FCS ACCESS Fit (Carl Zeiss-Evotec)
software package using a Marquardt nonlinear least-squares algorithm for a one-
component fitting model112. The average hydrodynamic radius Rh of the protein was





where kB is the Boltzmann constant (1.38 × 10−23 J/K), T is the temperature (293 K),
and η is the viscosity of the solvent (0.001 kgm−1 s−1). The molecular weight of the





where NA is Avogadro’s number= 6.023 × 1023mol−1, and ρ is the mean density of the
molecule. By titrating 40–0.2 µM SPOC to 15 nM of Atto-488 labeled peptides 2xpS2 or
2xpS2pS5, the diffusion times significantly increased from 74.4 ± 2.7 µsec (2xpS2) or
75.0 ± 0.9 µsec (2xpS2pS5) for peptide alone to 133.0 ± 7.8 µsec (2xpS2-SPOC) or
127.0 ± 5.0 µsec (2xpS2pS5-SPOC) for SPOC-bound peptides (Supplementary Fig. 3).
The calculated corresponding molar masses of 1.9 ± 0.2 kDa (2xpS2), 2.0 ± 0.1 kDa
(2xpS2pS5), 17.9 ± 3.6 kDa (SPOC), 20.3 ± 3.8 kDa (2xpS2-SPOC) and 17.7 ± 2.2
(2xpS2pS5-SPOC) clearly showed a 1:1 binding stoichiometry (Supplementary Fig. 3c).
Mass photometry. Mass photometry measurements were performed on a Refeyn
OneMP mass photometer using AcquireMP software (v2.3.0). Marienfeld high
precision glass coverslips (24 × 50 mm, No. 1.5H) were cleaned by sequential
sonication in Milli-Q H20, isopropanol (HPLC grade), and Milli-Q H2O (5 min
each), followed by drying with a clean nitrogen stream. Clean coverslips were
equipped with self-adhesive silicone culture wells (Grace Bio-Labs reusable Cul-
tureWellsTM gaskets). In total 18 µl buffer (50 mM Tris pH 8, 300 mM NaCl,
0.5 mM TCEP) were pipetted into a culture well and the focal position was
identified, then PHF3 was added to a final concentration of 20 nM and movies of
60 s duration were recorded using default settings and medium field of view
(imaged area: 10.8 µm × 6.8 µm). Mass photometry data were processed and ana-
lyzed using DiscoverMP software (v2.4.0). Contrast-to-mass calibration was per-
formed using Invitrogen NativeMarkTM Unstained protein standard containing
proteins of the masses 1048 kDa, 480 kDa and 146 kDa.
X-ray crystallography. Due to the low sequence identity with published SPOC
domain structures of human SHARP and Arabidopsis FPA, PHF3 SPOC structure
was solved using the single-wavelength anomalous diffraction (SAD) method.
Initial crystals of SPOC at 5 mg/mL were obtained using the sitting-drop vapor
diffusion technique and a nanodrop-dispensing robot (Phoenix RE; Rigaku Eur-
ope). Crystallization conditions were optimized using microseed matrix screening
approach (MMS)113. The best diffracting crystals were grown in conditions B3
from ShotGun HT screen (SG1 HT96 Molecular Dimensions, Suffolk, UK) con-
taining 0.2 M MgCl2, 0.1 M Bis-Tris pH 5.5, 25% PEG 3350 at 22 °C. For co-crystal
structures, a 3-fold molar excess of 2xpS2 (Clonestar), 2xpS2pS5 (Clonestar) and
2xpS2pS7 CTD (Eurogentec) peptides was incubated with 5 mg/mL of SPOC. Co-
crystals were grown using the sitting-drop vapor diffusion technique. The best
diffracting crystals of SPOC:2xpS2 were obtained using MMS approach in Mor-
pheus screen E9 conditions (Morpheus HT, Molecular Dimensions) containing
0.12M ethylene glycol mixture, 0.1 M Tris-Bicine buffer pH 8.5, 20% glycerol and
10% PEG 4000; crystals of SPOC:pS2pS7 were obtained in JCSG C4 conditions
(JCSG HT96, Molecular Dimensions) containing 0.1 M Hepes pH 7.0, 10% PEG
6000; crystals of SPOC: 2xpS2pS5 were obtained in Morpheus A3 conditions
containing 0.03 M MgCl2, 0.03M CaCl2, 0.1 M imidazole-MES pH 6.5, 20% gly-
cerol and 10% PEG 4000. The crystals were flash cooled in liquid nitrogen prior to
data collection. The selenomethionine data set was collected at the beamline ID29
(ESRF, Grenoble) at 100 K at the peak of selenium using a wavelength of 0.979 Å.
The data sets of SPOC-CTD peptide complexes were collected at the MASSIF
beamline ID30a1 (ESRF, Grenoble) at 100 K using a wavelength of 0.966 Å. The
data set of SPOC:2xpS2pS5 was collected at the beamline ID29 (ESRF, Grenoble)
using a wavelength 1.07 Å. The data frames were processed using the XDS
package114, and converted to mtz format with the program AIMLESS115. The apo-
SPOC structure was solved using single anomalous diffraction with the CRANK
2 software suite116. The structures of SPOC in complex with 2xpS2, 2xpS2pS5, and
2xpS2pS7 CTD peptides were solved using the molecular replacement program
PHASER117 with atomic coordinates of apo-SPOC as a search model. The struc-
tures were then refined with REFMAC115,118 and Phenix Refine119 and rebuilt
using Coot120. The structures were validated and corrected using PDB_REDO
server121. The figures were produced using the PyMol software. Coordinates were
deposited in the protein data bank (accession codes: 6IC8 for PHF3 SPOC:2xpS2,
6IC9 for PHF3 SPOC:2xpS2pS7, 6Q2V for PHF3 SPOC, 6Q5Y for PHF3
SPOC:2xpS2pS5). Data collection and refinement statistics are reported in Sup-
plementary Table 2. The crystal structure of 2xpS2pS5 CTD peptide bound to
PHF3 SPOC showed a different binding mode compared to 2xpS2 and 2xpS2pS7
CTD peptides (Supplementary Fig. 2i–m). Two molecules of SPOC were bound to
2xpS2pS5 peptide, the conformation of the bound peptide was slightly different
and three phosphorylated CTD residues (pS5 from the first heptapeptide and
pS2pS5 from the second) were forming hydrogen bonds with SPOC residues
(Supplementary Fig. 2i–m). SPOC residues K1267 and K1309 from the SPOC_C
molecule and R1297 from SPOC_A formed hydrogen bonds with pS5a; R1248
from SPOC_C with pS2b; and R1248 and R1295 from SPOC_C and K1260 from
SPOC_A hydrogen bonded with pS5b) (Supplementary Fig. 2m). In sum, both
positively charged patches from two SPOC molecules contributed interchangeably
to the docking of the three phosphorylated serines (Supplementary Fig. 2m). While
2xpS2 structures indicate that the positive patches on the SPOC surface are geared
to accommodate pS2 marks on adjacent repeats, 2xpS2pS5 structure reveals that
the binding site can also adjust itself towards binding of phosphomarks within the
same repeat. However, the FCS measurements showed a 1:1 binding stoichiometry
for both 2xpS2 and 2xpS2pS5 peptides (Supplementary Fig. 3), confirming the data
from the crystal structure of 2xpS2 and 2xpS2pS7. This indicates that 2:1 stoi-
chiometry (SPOC:peptide) observed in the 2xpS2pS5 co-structure is most likely an
artefact of crystal packing.
In vitro condensate formation. 4-well glass bottom slides (Ibidi) were coated with
1% PF127 (Sigma Aldrich) overnight at 4 °C and washed twice with 25 mM Tris-Cl
pH 7.5, 50 mM NaCl, 1 mM DTT and 10% v/v PEG6000. Protein samples were
loaded onto glass slides, mixed with the buffer to reach the final concentration of
20 mM Hepes pH 7.4, 150 mM NaCl, 1 mM TCEP, 10% dextran T500 (Pharma-
cosmos) and imaged within 15–45 min. PHF3 and Pol II were prepared by mixing
Alexa labeled and unlabeled protein at 1:5 ratio. CTD and Pol II were phos-
phorylated with DYRK1A (generously provided by Matthias Geyer) in kinase
buffer (50 mM Hepes pH 7.5, 34 mM KCl, 7 mM MgCl2, 5 mM β-glyceropho-
sphate, 2.5 mM DTT) with 1 mM ATP for 1 h at 30 °C. The reaction was desalted
with PD MiniTrap G-25 (GE Healthcare) to remove MgCl2 and ATP that could
interfere with LLPS. Imaging was performed on Zeiss Axio Observer Z1 with a 60x
oil immersion objective. Condensate size was analyzed using Fiji.
In vitro fluorescence recovery after photobleaching (FRAP). Condensates were
prepared as described above and imaged on a Zeiss AxioObserverZ1 equipped with
a Yokogawa CSU-X1-A1 Nipkow spinning disc unit (pinhole diameter 50 μm,
spacing 253 μm) (Visitron) with an EM-CCD: back-illuminated evolve EM512
highspeed/high-resolution camera (Evolve™ EMCCD; Photometrics) using an EC
Plan-NeoFluor 100x/1.30NA Oil objective lens. Equipment control and imaging
was handled by Visiview software (version 5.0.0.11; Visitron). The 561 nm laser
line was used at full laser intensity (200 mW) to photobleach a circular region
within condensates to 40–50% of its initial intensity with 1 ms pixel dwell time.
Fluorescence recovery was imaged every 300 ms over a period of 3 min using
561 nm laser line at 20% intensity. The fluorescence intensity of the bleached
region was background-corrected and normalized to the fluorescence intensity
prior to bleaching. Bleaching correction was based on measuring the fluorescence
intensity in a similarly sized unbleached region within the condensate. The
obtained recovery curves were fit to a single exponential recovery (one-phase
association, Y= Y0 + (Plateau-Y0)*(1-exp(-K*x)) where Y represents the fluor-
escence intensity, Y0 the fluorescence intensity at timepoint 0, K the rate constant
and x the time.) using GraphPad Prism 6.04.
Immunofluorescence. Cells were grown on glass coverslips, washed with PBS or
with PEM buffer (100 mM Pipes, 5 mM EGTA, 2 mM MgCl2, pH 6.8) for the
neurons and astrocytes and fixed in 4% paraformaldehyde for 10 min. After rinsing
with PBS, the cells were permeabilized with a 0.1% Triton X-100 solution in PBS
for 8 min, rinsed again and blocked for 1 h RT in blocking buffer (0.1% Tween, 1%
BSA in PBS). Coverslips were incubated with the primary antibodies for 1 h RT,
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washed and subsequently incubated with secondary Alexa-conjugated antibodies
for 1 h RT. After washing, coverslips were stained with DAPI and mounted on glass
slides in ProLong Gold antifade reagent (Life technologies). Images were acquired
using an LSM710 confocal microscope and processed with ImageJ software.
EU incorporation assay. HEK293T PHF3 WT, KO and ΔSPOC cells were grown
for 24 h in 24-well plates for FACS analysis or on coverslips for immuno-
fluorescence. Cells were then incubated with 0.5 µM EU (Molecular Probes) for 1 h.
For immunofluorescence, cells were fixed in 2% PFA, washed in 3% BSA in PBS
and permeabilized in 0.5% Triton X-100 in PBS. Click-iT® reaction was performed
to couple Alexa Fluor 488 Azide (Molecular Probes) to the incorporated EU. Cells
were subsequently stained with DAPI and coverslips were mounted on glass slides
with ProLong Gold. For FACS analysis, cells were harvested by trypsinization,
washed in PBS and fixed overnight in 75% methanol at −20 °C. Fixed cells were
washed with PBS, blocked in 3% BSA and permeabilized in 0.25% Triton X-100 in
PBS. Click-iT® reaction was performed to couple Alexa Fluor 488 Azide to the
incorporated EU. Cells were subsequently washed twice in 3% BSA in PBS and
finally resuspended in PBS. FACS measurements were performed on BD Fortessa
machine using Diva software. A population of approximately 104 cells was analyzed
for each sample and cell counts in the gated P1 population were measured for three
independent experiments using Flowing Software version 2.5.1. Cell counts for
each fluorescence intensity were also exported in Microsoft Excel 2010 as frequency
distributions of arbitrary fluorescence unit values. Average distributions of three
independent experiments were plotted to generate the final FACS data histograms.
High-resolution Airyscan imaging. Cells were grown for at least 16 h on high
precision glass coverslips (#1.5) coated with 0.5 µg/ml fibronectin in PBS for 2 h at
RT. For EU incorporation assay cells were incubated with 0.5 µM EU (Molecular
Probes) for 1 h, washed in PBS and fixed in 2% PFA for 15 min at RT. Fixed cells
were washed twice in 3% BSA in PBS, permeabilized in 0.5% Triton X-100 in PBS
for 10 min and washed twice in PBS. Click-iT® reaction was performed to couple
Alexa Fluor 647 Azide (Molecular Probes) to the incorporated EU. For IF cover-
slips were incubated with primary antibodies in 3% BSA, 0.1% Tween in PBS ON at
4 °C and subsequently incubated with Alexa Fluor secondary antibodies for 1 h at
RT, counterstained with DAPI and mounted in ProLong Diamond antifade reagent
(Life Technologies). Airyscan imaging was perfomed on an inverted Zeiss LSM 980
confocal microscope equipped with a 63x/1.4 Oil DIC objective and a 32 channel
GaAsp Airyscan 2 detector unit controlled by Zen Black (software version 3.2).
Sequential acquisitions of up to 4 channels were performed with 30 mW laser
diodes (405 nm and 488 nm), a 25 mW DPSS laser (561 nm) and a 25 mW HeNe
laser (639 nm) set to 1–3% excitation power. Images were captured with 2x Nquist
settings (pixel size 40 nm, z interval 150 nm) with a pixel dwell time of ~ 6.6 µs and
processed for superresolution with Airyscan filter 6. The resulting 3D high-
resolution images were analyzed with the Zeiss co-localization plugin of Zen 3.2.
Individual nuclei identified by DAPI were marked as regions of interest and
thresholds were determined by Costes regression and randomization. Fluorescence
intensity in co-localized clusters was quantified with Fiji 3D objects counter
(ImageJ 1.53c). Colocalization coefficients for each cell were averaged across all
slices of the z-stack and plotted for each cell individually. Box and whisker plots
were generated from ~ N= 20 cells of at least two biological replicates.
PRO-seq. The protocol was adapted from Kwak et al, 2013. To isolate nuclei, cells
were resuspended in cold buffer A (10 mM Tris-Cl pH 8, 300 mM sucrose, 3 mM
CaCl2, 2 mM MgAc2, 0.1% TritonX-100, 0.5 mM DTT), incubated on ice for 5 min
and transferred to a dounce homogenizer. After douncing 25 times with the loose
pestle, cells were centrifuged at 700 g for 5 min. The pellet was resuspended again
in buffer A, centrifuged and resuspended in cold buffer D (10 mM Tris-Cl pH 8,
25% glycerol, 5 mM MgAc2, 0.1 mM EDTA, 5 mM DTT), flash frozen with liquid
nitrogen and stored at –80 °C. For each run-on, 107 HEK293 nuclei were mixed
with 106 of Drosophila S2 nuclei (10% for spike-in normalization) in 100 µL buffer
D and incubated at 30 °C for 3 min with 0.025 mM biotin-11-NTPs and run-on
master mix (5 mM Tris-Cl pH 8, 2.5 mM MgCl2, 0.5 mM DTT, 150 mM KCl, 0.2
units/µL SUPERase In, 0.5% Sarkosyl). Nascent RNA was isolated using TRIzol LS
reagent according to the manufacturer’s instructions, denatured at 65 °C for 40 s,
hydrolyzed using 0.2 M NaOH on ice for 20 min and neutralized with 1 volume of
1M Tris-Cl pH 6.8. Buffer was exchanged with DEPC water using BioRad P-30
columns. Fragmented nascent RNA was subsequently enriched using Streptavidin
M280 beads by rotating the samples for 20 min in binding buffer (10 mM Tris-Cl
7.4, 300 mM NaCl, 0.1% TritonX-100). Beads were subsequently washed twice with
high-salt wash buffer (50 mM Tris-Cl pH 7.4, 2 M NaCl, 0.5% TritonX-100), twice
with binding buffer, and once with low-salt wash buffer (5 mM Tris-Cl pH 7.4,
0.1% TritonX-100). RNA was isolated from the beads using TRIzol reagent in two
consecutive rounds and pooled together for ethanol precipitation. The RNA pellet
was redissolved in DEPC H2O with 10 pmol of reverse 3′ RNA adaptor starting
with a 5’ random octamer sequence (5′- 5Phospho rNrNrNrNrNrNrNrNrGrAr-
UrCrGrUrCrGrGrArCrUrGrUrArGrArArCrUrCrUrGrArArC-/inverted dT/ −3′)
and subjected to ligation using T4 RNA ligase I (NEB) at 16 °C ON. RNA was
isolated using Streptavidin M280 beads as previously described and 5’ ends were
repaired using Cap-Clip Acid Pyrophosphatase (Cellscript) and Polynucleotide
Kinase (PNK, NEB) according to manufacturers’ instructions. RNA was purified
again with TRIzol and ethanol precipitation as before and subjected to 5′ RNA
adaptor ligation as for the 3′ adaptor ligation (the 5′ adaptor contained a 3′ random
tetramer sequence 5′- rCrCrUrUrGrGrCrArCrCrCrGrArGrArArUr-
UrCrCrArNrNrNrN −3′). RNA was enriched by a third round of binding to
Streptavidin M280 beads and TRIzol isolation. RNA was retro-transcribed using
RP1 Illumina primer and SuperScript III (Invitrogen) to generate cDNA libraries.
Libraries were then amplified using KAPA HiFi Real-Time PCR Library Amplifi-
cation Kit (Peqlab) and Illumina primers containing standard TruSeq barcodes.
Amplified libraries were subjected to electrophoresis on 2.5% low melting agarose
gel and amplicons from 150 to 300 bp were excised, purified from the gel using
NucleoSpin Gel and PCR Clean-up kit (Macherey-Nagel) and sequenced on Illu-
mina HiSeq 2500 platform (VBCF NGS facility).
Transcription elongation inhibition with DRB and release. PHF3 WT, KO and
ΔSPOC HEK293T cells were grown in 15 cm dishes and incubated with 100 µM
DRB (Sigma) or DMSO for 3.5 h. Cells for time point 0 were harvested immedi-
ately. Alternatively, cells were washed twice with PBS and allowed to recover in
normal medium for 10, 25, or 40 min before harvesting. Cells were harvested and
immediately processed for nuclei isolation as described in the PRO-seq section.
RNA isolation, RT-qPCR and RNA-seq library preparation. RNA was isolated
from harvested cells using TRI reagent (Sigma) according to the manufacturer’s
instructions. cDNA was obtained by reverse transcription of 1 µg of RNA using
random hexamer primers (Invitrogen) and ProtoScript II Reverse Transcriptase
(NEB) according to manufacturers’ instructions. RT-qPCR was performed on a
BioRad CFX384 Touch qPCR cycler using iTaq Universal Sybr Green Supermix
(BioRad). Biorad CFX Maestro software was used to determine Ct values. RT-
qPCR data were analyzed by normalizing the expression of the genes of interest by
GAPDH housekeeping gene expression; gene expression was calculated after
assessing primers efficiency. For RNA-seq, 8 × 106 HEK293 cells were mixed with
2 × 106 Drosophila S2 cells for spike-in normalization. Total isolated RNA was first
treated with recombinant DNaseI (Roche), cleaned up using peqGOLD PhaseTrap
A tubes (Peqlab), and rRNA-depleted using the Ribo-Zero kit (Illumina). RNA-seq
libraries were prepared using the NEBNext Ultra II directional RNA library pre-
paration kit (NEB) according to the manufacturer’s instructions. Sequencing was
performed on Illumina HiSeq 2500 (VBCF NGS facility).
Chromatin immunoprecipitation. Cells were harvested, counted, resuspended in
50 mL PBS/108 cells and fixed for 10 min by adding formaldehyde to a final
concentration of 1%. Formaldehyde was quenched by adding glycine pH 3 to a
final concentration of 0.6 M for 15 min. Cells were centrifuged and washed twice in
cold PBS. To isolate nuclei, 108 fixed cells were resuspended in 5 mL cold lysis
buffer 1 (50 mM Hepes/KOH pH 7.5, 140 mM NaCl, 1 mM EDTA, 10% glycerol,
0.5% Nonidet P-40, 0.25% Triton X-100, 1x protease inhibitor; for Pol II ChIP
2 mM Na3VO4 and 2 mM NaF), rotated for 10 min at 4 °C and centrifuged. Nuclei
were resuspended in 5 mL cold lysis buffer 2 (10 mM Tris-Cl pH 8, 200 mM NaCl,
1 mM EDTA, 0.5 mM EGTA, 1x protease inhibitors; for Pol II ChIP 2 mM Na3VO4
and 2 mM NaF), rotated for 10 min at room temperature and centrifuged. The
pellet was resuspended in 3 mL lysis buffer 3 (10 mM Tris-Cl pH 8, 100 mM NaCl,
1 mM EDTA, 0.5 mM EGTA, 0.1% Na-deoxycholate, 0.5% N-lauroylsarcosine, 1x
protease inhibitors; for Pol II ChIP 2 mM Na3VO4 and 2 mM NaF). Chromatin
was sheared to an average size of 200–600 bp using the Bioruptor Pico (Diagenode)
for 20 cycles, 30 s on/30 s off. Triton X-100 was added to a final concentration of
1%. In total 5–10% of chromatin was kept as an input, to the remainder antibody
(Pol II pS5 3E8; Pol II pS2 3E10; Pol II pS7 4E12; total Pol II clone F-12 Santa Cruz
sc-55492; TCEA1 Abcam ab185947; H3K27me3 Millipore 07–449) or antiserum
(GFP Abcam ab290) was added and rotated ON at 4 °C. Antibody and cell amounts
are indicated in the key resources table. For TFIIS, Pol II F-12, and H3K27me3
ChIP, chromatin was mixed with 2.5% of mouse chromatin as a spike-in before
adding the antibody. Protein G or protein A Dynabeads were washed three times in
cold block solution (0.5% BSA in PBS), antibody-bound chromatin was added to
the beads and rotated 4–6 h at 4 °C. Beads were washed 5 times (8 times for Pol II
pS5 ChIP) in RIPA washing buffer (50 mM Hepes/KOH pH 7.5, 500 mM LiCl,
1 mM EDTA, 1% NP-40, 0.7% Na-deoxycholate) and once in 50 mM NaCl in TE.
Crosslinked protein-DNA complexes were eluted in 200 µL elution buffer (50 mM
Tris-Cl pH 8, 10 mM EDTA, 1% SDS) for 15 min at 65 °C. Crosslinks were reversed
at 65 °C ON. RNA was degraded by adding 0.2 mg/mL RNase A for 2 h at 37 °C,
proteins were digested by adding 0.2 mg/mL proteinase K and 5.25 mM CaCl2 for
30 min at 55 °C. DNA was purified by phenol-chloroform extraction, ethanol-
precipitated, and resuspended in 50 µL nuclease-free water. Next generation
sequencing libraries were prepared using the NEBNext Ultra II DNA library Prep
Kit for Illumina and NEBNext Multiplex Oligos Primer Set 1–3 (New England
Biolabs) according to the manufacturer’s instructions. Next generation sequencing
was performed on Illumina HiSeq 2500, NextSeq 550 or NovaSeq 6000 (VBCF
NGS facility). ChIP-qPCR analysis of input and ChIP-DNA was performed on a
BioRad CFX384 Touch cycler using Takyon No Rox SYBR MasterMix dTTP Blue
(Eurogentec). Data were analyzed by calculating the %input value, values were
averaged from three independent experiments.
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Pol II phosphorylation, elongation complex (EC) preparation, and sucrose
gradient ultracentrifugation. Pol II was phosphorylated with DYRK1A kinase as
described above. A nucleic acid scaffold for transcribing Pol II was assembled by
mixing equimolar amounts of DNA (EC-phf3-template) and RNA (RNA50) in a
BioRad T100 Thermal Cycler heated to 95 °C and cooled in 0.1 °C/s increments
until 4 °C was reached. For sucrose gradient ultracentrifugation, the Pol II-EC was
assembled by incubating 60 pmol Pol II with a 2-fold molar excess of DNA/RNA
for 10 min on ice, followed by 10 min at 30 °C, and another 10 min at 30 °C after
adding a 4-fold molar excess of non-template DNA (EC-phf3-nontemplate) to
generate a transcription bubble. A 4-fold molar excess of PHF3 or TFIISM/TFIISM
+TFIIF was incubated with Pol II-EC for 20 min at 25 °C, followed by addition of
the 4-fold molar excess of the competitor (TFIISM/TFIISM+TFIIF or PHF3
respectively) for 20 min at 25 °C. 10–30% sucrose gradients were prepared using a
gradient mixer (Gradient Master 108; BioComp Instruments). Pol II complexes
were applied on top of the gradient followed by ultracentrifugation 105169 g in a
SW60 swinging bucket rotor (Beckman Coulter) for 16 h at 4 °C. 80 µl fractions
were collected carefully from top to the bottom of the tube and analyzed by
Western blotting.
In vitro transcription elongation assay. Pol II phosphorylation and transcription
bubble assembly were performed as above, using arrest sequences comprising a
region for EC assembly and a region containing a previously characterized Pol II
arrest site shown to be responsive to TFIIS (Arrest-template/5′-FAM-Arrest-RNA
and Arrest-nontemplate)122. 0.12 µM Pol II was used per reaction. A total of
0.1 µM TFIIS and different concentrations of PHF3 or PHF3 ΔTLD were added to
Pol II-EC and incubated for 5 min at 30 °C. Transcription was initiated by adding
100 µM of NTPs in a transcription buffer (20 mM Hepes pH 7.5, 75 mM NaCl,
3 mM MgCl2, and 4% glycerol) and incubating at 37 °C for 10 min. Final ATP
concentration was 200 µM due to the leftover from the kinase reaction. Reaction
were stopped by adding urea loading buffer (4 M urea in TBE) and EDTA
(12.5 mM) and boiling at 95 °C for 5 min. After chilling on ice, samples were
incubated with 0.1 mg/mL proteinase K at 37 °C for 20 min, boiled at 95 °C for
5 min and chilled on ice before loading on a 20% denaturing acrylamide gel. Gels
were run at 300 V for 1.5 h and scanned using Typhoon (GE Healthcare).
SLAM-seq. SLAM-seq was performed as described50. HEK293T cells seeded into
6 cm dishes the day before the experiment were incubated in standard culture
medium containing 100 µM 4-thiouridine (s4U; ChemGenes) for 12 h with media
exchanges every 3 h. Subsequently, cells were washed twice with PBS and incubated
with 10 mM uridine-containing medium. Cells were harvested using TRI reagent
(Sigma) at timepoints 0 h, 6 h, and 12 h after removal of s4U. RNA was isolated
according to the manufacturer’s instructions including 0.1 mM DTT during iso-
propanol precipitation and resuspended in 1 mM DTT. Isolated RNA was treated
with 10 mM iodacetamide to alkylate s4U and subjected to ethanol precipitation.
Alkylated RNA was resuspended in water and treated with TURBO DNA-free Kit
(Invitrogen) according to the manufacturer’s instructions. For global SLAM-seq,
libraries were prepared using QuantSeq 3′ mRNA-Seq Library Prep Kit FWD for
Illumina (Lexogen) according to the manufacturer’s instructions. For targeted
analysis of INA, RNA was reverse transcribed using oligo(dT) primer. Subse-
quently, RNA was removed using RNAse H (NEB) according to the manufacturer’s
instructions and cDNA was amplified using INA-specific forward primer (5′- CA
CGACGCTCTTCCGATCTNNNNNNTCTGTCCAGCAGTCACTTCG-3’) and
oligo(dT) primer (5′-GTTCAGACGTGTGCTCTTCCGATCT-(T)n-V-3′) for 23
cycles. Library amplification was performed using Illumina FWD (5′- AATGATA
CGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTTCCGAT
CT-3′) and REV (5′- CAAGCAGAAGACGGCATACGAGATNNNNNNGTGAC
TGGAGTTCAGACGTGTGCTCTTCCGATCT-3′) index primers. Next genera-
tion sequencing was performed at the VBCF NGS facility using Illumina
NextSeq 550.
Genomic region definition. To reliably quantify gene activity, transcription start
sites (TSS) and gene body regions were precisely defined. TSS for HEK293 cells
were extracted from the FANTOM5 data set (24670764), and transferred from
hg19 to the hg38 version of the human reference genome using liftOver
(16381938). Regions which mapped to multiple locations were disregarded. Each
Fantom TSS was extended into a promoter region of ±250 bp from the putative end
of the TSS region. Gene body regions were defined in the following way. Firstly,
gene models were downloaded from the Ensembl database (27899575) on
02.10.2015. Each promoter region was assigned to the nearest transcript on the
corresponding strand from the Ensembl annotation; promoters that were >2 kb
away from a transcript were removed from the data set. Gene body region was
defined as a region from the promoter end (+250 bp from the TSS) to the most
commonly annotated transcript end for the corresponding gene (a transcript end
which is supported by highest number of annotated isoforms). If multiple tran-
script ends had the same support, the longest isoform was chosen as the repre-
sentative. If the corresponding transcript overlapped with multiple defined TSS
regions, a representative promoter was chosen for each gene by selecting the TSS
with the highest average PRO-seq signal.
Analysis of PRO-seq data. Prior to quantification of PRO-seq data, genomic
regions containing genes were split into promoter regions and gene bodies. PRO-
seq data were mapped to the hg38 version of the human reference genome using
the STAR- 2.4.0 (23104886) aligner with the following
parameters:–outFilterMultimapNmax 10–outFilterMismatchNoverLmax
0.2–sjdbScore 2. PRO-seq signal in the promoter area was quantified by counting
the number of read 5′ ends overlapping with the defined promoter regions, while
the PRO-seq signal within the gene body was quantified by counting the number of
read 5′ ends overlapping the gene body. PRO-seq counts for each region and each
sample were normalized to Drosophila S2 spike-in by multiplying the corre-
sponding counts with the ratio between the total number of human and Drosophila
reads. Differential analysis was performed using DESeq2123. Spike-in calculated
normalization factors were normalized to have geometric mean of 1, prior to the
differential analysis. To avoid the possibility of quantifying transcriptional read-
through from highly expressed genes, all genes which had wild type PRO-seq
RPKM > 8 in a 250 bp region 250 bp upstream of the promoter region were filtered
out of the analysis. Additionally, all non-expressed genes (genes with promoter
RPKM < 2 in all samples) were also filtered from the analysis. PRO-seq data was
deposited under the accession number E-MTAB-7501.
Validation of PRO-seq data. The quality of PRO-seq data was evaluated using the
WT sample, which showed that the most highly expressed genes are microRNAs,
histones, Pol II and Jun, as already reported. We compared the expression values in
the TSS regions between FANTOM5 data based on Cap Analysis of Gene
Expression (CAGE) of mRNAs and our PRO-seq data containing nascent RNAs
(Supplementary Fig. 10). We obtained a high Spearman correlation between our
data and the CAGE data (0.57) and we observed a spread in the PRO-seq data
where CAGE data have low signal, indicating that PRO-seq captures the signal in a
much lower dynamic range. In addition, we compared the PRO-seq data with the
NET-seq from HEK293 cells for the TSS regions124. NET-seq data bigWig files
were downloaded from the GEO database (GSE61332), and transferred from the
hg19 to hg38 genome versions using CrossMap125. The NET-seq signals were
summarized using the Bioconductor package genomation and compared to the
average normalized PRO-seq signal using the Spearman correlation coefficient. The
correlation was visualized using ComplexHeatmap126. The Spearman correlation
between PRO-seq and NET-seq samples was >0.85, which confirms that the data
are of high quality. The heatmap shows the correlations between PRO-seq data for
PHF3 WT, KO, ΔSPOC, and NET-seq data (Supplementary Fig. 10b).
Leading edge definition for elongation rate calculation. PRO-seq DRB time-
course data were mapped as described above. Genomic tracks were constructed
from the mapped data (in a strand specific manner), and normalized to Drosophila
spike-in. Leading edge definition was performed using a heuristic algorithm, which
joins regions of increased read density in a strand specific manner. The analysis
was performed on difference genomic tracks, where the 0 min time point was
subtracted from each subsequent time point. This was done to prevent merging of
the signal from genes in head to tail orientation. First, the genome was split into
1 kb non-overlapping tiles, the number of bases covered in each tile was counted,
and the coverage in each tile was summed. To smoothen the signal, number of
covered bases in each tile was calculated as max(countsn-1, countsn)—a maximum
of the current and the preceding tile, in a non-iterative way. Tiles with less than
25% of bases covered, and a minimal normalized signal value of 0.1 (sum of
coverage over the tile) were removed from the analysis. From the resulting tiles, a
contiguously expressed region was constructed by merging tiles within 4 kb. All
regions shorter than 3 kb were filtered out from further analysis. Each contiguously
expressed region was annotated to the gene with the closest upstream TSS. Genes
with the expressed region defined in all time points for all conditions were kept for
further analysis. PRO-seq data from the DRB time-course experiment was
deposited under the accession number E-MTAB-8278.
Analysis of ChIP-seq data. PHF3, Pol II (F-12), TFIIS and H3K27me3 ChIP-seq
data were mapped to the hg38 version of the human genome using Bowtie2127 with
the following parameters: bowtie2 -k 1. TFIIS, Pol II (F-12), and H3K27me3 ChIP-
seq samples were normalized using mouse chromatin spike-in and mapped sepa-
rately to the human (hg38) and mouse (mm10) genomes, using Bowtie2, as
implemented in PigX pipeline128. The scaling factor was obtained by dividing the
total number of uniquely mapped reads to the human genome, with the number of
uniquely mapping reads to the mouse genome. The genomics tracks were then
constructed by extending the reads to 200 bp into 3′ direction, calculating the
coverage vector, and scaling using the aforementioned scaling factor. PHF3 ChIP-
seq data was deposited under the accession number E-MTAB-8783. Pol II (F-12),
TFIIS and H3K27me3 ChIP-seq data was deposited under the accession number E-
MTAB-8789.
Construction of genomic tracks. Genomic tracks were constructed by merging all
replicates of the corresponding biological conditions (WT, KO, ΔSPOC) and
experiments (RNA-seq, PRO-seq, ChIP-seq, SLAM-seq). Merged tracks were then
normalized to the total number of reads. For ChIP-seq, the reads were firstly
extended to 200 bp towards the 3’ end, the coverage was calculated, and normalized
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to the total number of reads. The tracks were additionally normalized by taking the
log2 ((ChIP +1) / (Input+1)). Negative values were censored to zero.
Signal profile construction. Signal profiles were constructed by averaging the
signal from genomic tracks over different functional regions into 100 bins of equal
size. The extreme values in the profiles were avoided by applying the trimmed
mean function, with the trim parameter set to 0.3. To compare ChIP-seq profiles of
different antibodies (different proteins), the profiles were normalized prior to
averaging to the within region signal range by dividing the signal by min – max.
Analysis of HEK293T RNA-seq data. RNA-seq reads were mapped to a genome
comprising of human reference genome hg38 version and Drosophila melanogaster
version dm6. STAR- 2.5.3 was used with the default parameters and gencode v28
gtf annotation as gtf file. RNA-seq data were quantified using STAR quantMode.
Differential expression was analyzed using DESeq2 and the gene counts were
normalized to the total Drosophila spike-in counts; genes with an adjusted p-value
< 0.05 were designated as differentially expressed. HEK293T RNA-seq data was
deposited under the accession number E-MTAB-7498.
Analysis of mES RNA-seq data. Mouse embryonic stem cell RNA-seq data were
mapped to the mm9 version of the mouse reference genome using STAR- 2.4.0.
STAR index was constructed with gene annotation downloaded from the Ensembl
database on 20.05.2015. The expression was quantified and the differential
expression was analyzed as described previously. mESC RNA-seq data was
deposited under the accession number E-MTAB-7526.
Analysis of SLAM-seq data. Raw sequenced reads were processed with the
SLAMdunk pipeline as previously described50. Genes which had detectable con-
version rates in at least three biological replicates in all conditions were kept for
subsequent analysis. Furthermore, genes which had a non-monotonic decrease of
the median conversion rates were filtered out. To estimate the half-lives, a robust
linear model was fit on the linearized form of the exponential decay equation using
the RLM function from the MASS R package. SLAM-seq data was deposited under
the accession numbers E-MTAB-7898 and E-MTAB-7899.
Sequencing data integration. The complete data integration and data analysis
were done in R using Bioconductor129, and the following libraries:
GenomicAlignments130, data.table (Matt Dowle and Arun Srinivasan, 2017),
data.table: Extension of ‘data.frame’ (R package version 1.10.4-3.), biomaRt131,
GenomicRanges, rtracklayer132, SummarizedExperiment (10.18129/B9.bioc.Sum-
marizedExperiment), genomation133, and ggplot2 (10.1007/978-0-387-98141-3).
Differentiation of mESCs into neural stem cells, neurons, and astrocytes.
mESCs differentiation into neural stem cells (NSCs), and later in neurons and
astrocytes, was adapted from a previously described protocol134. Briefly, 104
mESCs/cm2 were seeded on gelatin-coated 10 cm dishes and cultured for 7 days in
N2B27 medium. After 7 days, 2–5 × 106 cells were transferred to non-gelatinized
T75 flasks in NS-N2B27 medium (N2B27 medium supplemented with 10 ng/mL
EGF and 10 ng/mL FGF2) and grown for 2–4 days to form aggregates in sus-
pension. The cell aggregates were then collected by centrifugation (105 g for 30 s)
and transferred to fresh gelatin-coated T75 flasks and grown in NS-N2B27 med-
ium. After 3 to 7 days, cells displayed NSCs morphology. For neuronal differ-
entiation, NSCs were seeded in NS-N2B27 medium at a density of 25000 cells/cm2
on laminin-coated glass coverslips in 24-well plates for immunofluorescence and
6-well plates for RNA isolation. The day after, the medium was replaced with
N2B27 medium supplemented with only 5 ng/mL FGF2. Cells grown on glass
coverslips were then fixed for immunofluorescence, while cells grown in 6-well
plates were harvested for RNA isolation at the indicated time points. Since cell
quantification was not possible due to the organization of WT differentiated cells
into tight aggregates, to quantify the differences between Phf3 WT and KO cells
upon neuronal differentiation we manually counted by fluorescence microscopy all
TuJ1 positive cell aggregates (referred to as “neuronal clumps”) on the glass cov-
erslips. For astrocyte differentiation, NSCs were seeded in N2B27 medium sup-
plemented with 1% FBS at a density of 50000 cells/cm2 on gelatin coated glass
coverslips in 24-well plates. Cells were fixed after 5 days and samples were pro-
cessed for immunofluorescence.
Exit from naive pluripotency assay of mESCs. mESCs were cultured in N2B27
medium (DMEM F12 + Neurobasal medium supplemented with 1% L-glutamine,
1% penicillin/streptomycin, 1% NEAA, B27 supplement, N2 supplement, 2-mer-
captoethanol) supplemented with 2i/LIF as previously described102 for at least two
passages. 104 cells were seeded in 6-well plates and grown for 36 h in N2B27me-
dium + 2i in the presence or absence of LIF. Subsequently, cells that were grown
without LIF were incubated in the absence of 2i to allow differentiation for 8 h and
24 h. After harvesting the cells, RNA was isolated to determine gene expression by
RT-qPCR.
Quantification and statistical analysis. Error bars represent standard deviation
estimated from three to four independent experiments. For Western blot band
intensity, EU fluorescence intensity and RT-qPCR analyses statistical significance
was calculated using one-tailed Student’s t-test. P-values smaller than 5% were
considered statistically significant and indicated with an asterisk (‘*’ for p < 0.05;
‘**’ for p < 0.01; ‘***’ for p < 0.001; ‘****’ for p < 0.0001). ChIP-seq, RNA-seq and
PRO-seq were performed in triplicates. SLAM-seq was performed in six replicates.
Statistical analysis on all sequencing data was performed using DESeq2. Statistical
significance of the differential expression/abundance was determined by two-tailed
Wald test, after appropriate normalization for each type of data.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
The data that support this study are available from the corresponding author upon
reasonable request. The source data are provided with this paper. The atomic coordinates
for the structures generated in this study have been deposited in the Protein Data Bank
under accession codes: 6IC8 for PHF3 SPOC:2xpS2, 6IC9 for PHF3 SPOC:2xpS2pS7,
6Q2V for PHF3 SPOC, 6Q5Y for PHF3 SPOC:2xpS2pS5. The sequencing data generated
in this study have been deposited in ArrayExpress under accession codes: E-MTAB-7498
(RNA-seq HEK293T), E-MTAB-8783 (PHF3), E-MTAB-8789 (Pol II F-12, TFIIS,
H3K27me3), E-MTAB-7501 (PRO-seq), E-MTAB-8278 (Pro-seq elongation rate), E-
MTAB-7898 and E-MTAB-7899 (SLAM-seq), E-MTAB-7526 (RNA-seq mESC). The
mass spectrometry proteomics data generated in this study have been deposited in the
ProteomeXchange Consortium via the PRIDE partner repository under accession code
PXD026292. The processed mass spectrometry and sequencing data are provided in
Supplementary Data 1–6. All other raw data generated in this study are provided in
Supplementary Data 7. Atomic coordinates used in this study are available in the Protein
Data Bank under accession codes 2RT5, 4BY7, 5KXF, 5IYB, 6GMH, 6IC8. The NET-seq
data used in this study are available in GEO under accession code GSE61332. The
ATAC-seq data used in this study are available in ArrayExpress under accession code
E-MTAB-6195. H3K4me3 ChIP-seq data used in this study are available from ENCODE
under accession code ENCSR000DTU. REST ChIP-seq data used in this study are
available from ENCODE under accession code ENCSR896UBV.
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